integrated report year ended december otsuka holdings co ltd integrated report corporate philosophy keeping corporate philosophy otsuka mottos jissho actualization sozosei creativity otsuka group strives creating pursue achieve otsuka innovative group supports lives people worldwide products wide range innovative creative products including pharmaceuticals functional beverages functional foods dedicated contributing cultivating culture dynamic corporate improving lives climate reflecting vision healthcare com human health people pany finding ways live harmony local worldwide communities natural environment global perspective contributing afflu ent healthier lives people otsukas goal become indispensable contributor peoples health worldwide otsuka group operates business goal becoming indispensable contributor peoples health worldwide fulfilling corporate philosophy every activity operations encompass two core businesses pharmaceutical business provides comprehensive health support diagnosis treatment diseases nutraceutical business helps peo ple maintain improve daytoday health endeavor create unchanging value improv ing peoples health worldwide continue provide value society nutraceuticalsnutrition pharmaceuticals otsuka holdings co ltd integrated report otsuka holdings otsukas goal business strategy business results csr governance finance general information dna otsuka generates innovative products tokushima world otsuka group soon celebrate th anniversary dna group cultivated ceaselessly years connected challenges group undertakes businesses share unwav ering corporate philosophy otsukapeople creating new products better health worldwide employees around world continuing create provide new values world day chemical raw materials bittern salt pan residues global company started tokushima origin otsuka group goes back busaburo otsuka founder otsuka group established otsuka seiyaku kogyobu naruto tokushima prefecture company ten employ ees started chemical raw material manufacturer making magnesium carbonate resi dues called bittern left taking salt seawater saltproduction industry widespread tokushima back meiji period tokushima one japans ten largest cities addition japans larg est indigo dye industry city boasted secondary industries pharmaceutical salt productions also prosperous agriculture forestry fishing industries reaped bounty nature modernization japan time entrepreneurial businesses began spring country seto inland sea coast area industry made effective use bittern areas nat ural salt pans emerged many companies tokushima participated industry group also founded trend marked beginning global company today operating countries regions employees worldwide otsuka holdings co ltd integrated report creation paradigm shifts giant tomato tree birthplace human resource development institute training center employees located tokushima japan several monuments depicting sozosei creativity concept lies root groups corpo rate philosophy one giant tomato tree whereas normal tomato plant yields fruits tomato tree puts forth around secret behind lies paradigm shift abandoned pre conception since tomato plants grow soil soil essential enabled us set tomato plants roots free soil using hydroponic cultivation instead drawing fecundity tomato tree yielded amount fruit one considered possible giant tomato tree monuments break preconceptions speak importance paradigm shifts also communicating message need remain company brimming creativity otsuka holdings co ltd integrated report otsuka holdings otsukas goal business strategy business results csr governance finance general information nevergiveup rd drug developed years effort brings hope renal disease treatment us dna group found displaying creativity others also stance challenging believe correct long period time nevergiveup spirit demonstration samscajinarcjynarque vreceptor antagonist grown core product otsuka group drug discovery project began physicians request want diuretic excretes water following years persistent research project came fruition launch aquaretic agent samsca typical company closing drug discovery project extending years midway would great surprise otsuka groups commit ment actualize corporate philosophyotsukapeople creating new products better health world wideled continuation research development eventually development product following launch expanded indications samscajinarcjynarque treatment autosomal dominant polycystic kidney disease adpkd disease curative medi cines nevergiveup rd opened new path treatment intractable kidney disease brand name adpkd treatment multiple regions outside japan brand name adpkd treatment us otsuka holdings co ltd integrated report supporting peoples health treatment diseases maintaining health innovative products developed dna diagnosis treatment pharmaceutical business psychiatry neurology area antipsychotic antipsychotic antipsychotic pseudobulbar affect abilify longacting injectable rexulti pba agent abilify maintena nuedexta cardiovascular oncology area renal system area areas anticancer agent anticancer agent aquareticadpkd curea breath agent highcalorie infusion ts lonsurf treatment diagnosis solution samscajinarc h pylori infection elneopanf jynarque ubit tablet unmet medical needs otsuka holdings co ltd integrated report otsuka group contributes health people worldwide creating innovative products encompass ing pharmaceutical business addresses unmet medical needs nutraceutical business ful fills yettobe imagined consumer needs maintenance improvement daytoday health nutraceutical business functional beverages pocari sweat oronamin c drink os tiovita drink functional foods nutritional supplements calorie mate gerbl nature made daiya foods products innersignal oronine h ointment yettobe imagined needs otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report trajectory otsukas growth chemical raw materials beverages pharmaceuticals history product development billions yen intravenous tiovita drink bon curry pocari calorie mate pletal nature made match abilify solution sweat japan oronine h oronamin c futraful mikelan uft mucosta crystal ts innersignal ointment drink meptin geyser japan sales trend nutraceuticals consumer products others pharmaceuticals st oa lr ut te iod n bra uv se inn eo su ss launched oronine h ointment launched oronamin c drink launched bon curry estab rl eis sh ee ad r cp hh inr sm tia tuc te eutical started diagnostics business launched innersignal established otsuka medical devices consumer cp eh ua tr im caa l diagnostics cosmedics dee vd ii cc ea sl nc products pharma consumer pharma cosmedics clinical clinical consumer cp eh ua tr im caa l c po rn os du um cte sr ceuticals products ceuticals nutrition otc nutrition products business clinical nc uli tn rii tc ioa nl otc diagnostics c po rn os du um cte sr expansion chemicals nutrition otc diagnostics otc clinical clinical nutrition otc chemicals chemicals nutrition nc otc clinical nc uli tn rii tc ioa nl otc chemicals nc chemicals nutrition chemicals chemicals nc chemicals nc nc chemicals foundation phase growth phase international business development phase expansion phase started chemical raw material manufacturer opened tokushima research institute aim inhouse drug development started aggressive global expansion pursuing global growth naruto tokushima prefecture japan numerous nutraceutical products opened new markets broadening groups business otsuka holdings co ltd integrated report since foundation chemical raw material manufacturer naruto tokushima prefecture otsuka group built intravenous solutions business spurred groups growth brought market succession familiar products consumers including oronine h ointment bon curry pocari sweat calorie mate well pharmaceuticals antipsychotic agent abilify drug firstintheworld mechanism action otsuka group diversified business con tinues grow steadily billions yen kenjano ulos gerbl lonsurf jinarc rexulti bodymaint shokutaku japan soyjoy samsca abilify equelle maintena sales trend nutraceuticals consumer products others pharmaceuticals st oa lr ut te iod n bra uv se inn eo su ss launched oronine h ointment launched oronamin c drink launched bon curry estab rl eis sh ee ad r cp hh inr sm tia tuc te eutical started diagnostics business launched innersignal established otsuka medical devices consumer cp eh ua tr im caa l diagnostics cosmedics dee vd ii cc ea sl nc products pharma consumer pharma cosmedics clinical clinical consumer cp eh ua tr im caa l c po rn os du um cte sr ceuticals products ceuticals nutrition otc nutrition products business clinical nc uli tn rii tc ioa nl otc diagnostics c po rn os du um cte sr expansion chemicals nutrition otc diagnostics otc clinical clinical nutrition otc chemicals chemicals nutrition nc otc clinical nc uli tn rii tc ioa nl otc chemicals nc chemicals nutrition chemicals chemicals nc chemicals nc nc chemicals foundation phase growth phase international business development phase expansion phase started chemical raw material manufacturer opened tokushima research institute aim inhouse drug development started aggressive global expansion pursuing global growth naruto tokushima prefecture japan numerous nutraceutical products opened new markets broadening groups business due change consolidated fiscal year fiscal ended december transitional period covering nine months april december nutraceuticals cosmedics cosmetics medicine otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report otsukas value creation model promoting creation value called health focus two core businesses capitals strengths human capital number employees unwavering diversity inclusion corporate philosophy creation value diverse human resources otsukas dna p jissho actualization sozosei financial capital creativity message president total assets billion p manufactured capital manufacturing bases intellectual capital rd expenses pharmaceutical business total healthcare billion diverse latephase development projects businesses projects projects phase ii later stages p brand social relationship capital companies countries regions brand strength established value creation natural capital otsukas original marketingp climate change water resources resource symbiosis environmental initiativesp scope otsuka holdings subsidiaries affiliated companies december otsuka holdings co ltd integrated report putting practice otsuka achieve become indispensable contributor peoples health worldwide health challenges businesses social value generate challenge addressing unmet medical needs unmet medical p needs comprehensive contributions psychiatry neurology cancer treatment p oncology pharmaceutical business creation autosomal dominant polycystic kidney disease p samscajinarcjynarque adpkd worlds therapeutic drug p infectious diseases creation deltyba one two new tuberculosis drugs half century p provision value called health scientific evidencebased products yettobeimagined creation ion supply drink communicates importance needs rehydration electrolyte replenishment p rehydration nutraceutical provision health value called nutrition business balanced nutrition p p healthy life expectancy product lines support expansion healthy life expectancy p consumer products business delicious safe reassuring healthy p businesses distribution system power materials contribute p sustainable society otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report contents otsuka holdings corporate philosophy dna otsuka generates innovative products supporting peoples health treatment diseases maintaining health innovative products developed dna trajectory otsukas growth otsukas value creation model otsukas goal business strategy financial highlights nonfinancial highlights message president feature second mediumterm management plan feature foundation supports growth strengths business results research development pharmaceutical business nutraceutical business consumer products business businesses otsuka holdings co ltd integrated report csr governance csr business activities corporate governance directors audit supervisory board members finance general information main data consolidated financial statements group structure overview main operating companies global network corporate information shareholder information integrated report beginning report fiscal otsuka holdings integrated annual report csr report issuing integrated report brings together financial information nonfinancial information report hope deepen stakeholders understanding group aims become indispensable contributor peoples health worldwide n reporting period n reference guidelines fiscal january december international integrated reporting framework iirc information january included sustainability reporting guidelines g gri iso n scope reporting environmental reporting guidelines edition principle report covers otsuka holdings co ministry environment ltd subsidiaries activities data restricted scope noted report precautions regarding forwardlooking statements medical information integrated report summarizes operating financial results otsuka integrated report unified brand name used product different holdings co ltd subsidiaries fiscal january december brand names different countries regions sake readability therefore also includes information regarding selected material events products may available countries may available differ occurred january date publication report contains ent brand names different indications different dosages strengths forwardlooking statements pertaining plans projections strategies prospects please note information regarding pharmaceutical products including otsuka group companies statements based upon current anal products development intended kind advertising promotion ysis belief light information available issuing date report medical advice actual results may therefore differ due risks uncertainties may affect otsuka group operations otsuka holdings co ltd integrated report financial highlights net sales rd expenses pharmaceutical business rd expenses rd expenses ratio net sales overseas pharmaceutical business pharmaceutical billion sales ratio billion business billion billion consolidated net sales grew pre vious year due growth sales three global products abilify maintena samsca jinarc rexulti growth drivers new drugs japan pharmaceutical busi ness well growth nutraceutical business overseas particularly functional foods busi ness europe us nutritional supplements business jgaap ifrs jgaap ifrs net sales overseas sales ratio rd expenses pharmaceutical business rd expenses ratio pharmaceutical business operating profit total assets ratio equity attributable owners operating profit operating profit total assets company billion margin billion total assets billion billion consolidated operating profit increased previous year due improvement profitability increase investment gains equity method nutraceutical busi ness despite decline operating profit pharmaceutical business due active rd invest ments impairment loss jgaap ifrs jgaap ifrs operating profit operating profit margin total assets ratio equity attributable owners company total assets profit attributable owners company profit attributable ratio profit annual dividend per share attributable owners company owners annual dividend per share b illion company e n dividend payout ratio billion consolidated profit increased pre vious year mainly due reversals deferred tax liability recorded us us tax reform jgaap ifrs jgaap ifrs profit attributable owners company ratio profit attributable owners company annual dividend per share dividend payout ratio otsuka holdings co ltd integrated report net sales rd expenses pharmaceutical business rd expenses rd expenses ratio net sales overseas pharmaceutical business pharmaceutical billion sales ratio billion business billion billion rd expenses pharmaceutical business increased previous year result active rd investments maximize product value core therapeutic areas psychiatry neurol ogy oncology cardiovascular renal system jgaap ifrs jgaap ifrs net sales overseas sales ratio rd expenses pharmaceutical business rd expenses ratio pharmaceutical business operating profit total assets ratio equity attributable owners operating profit operating profit total assets company billion margin billion total assets billion billion high ratio equity attributable owners parent total assets maintained strengthening competitiveness actively pursuing investments lead growth engage efficient management jgaap ifrs jgaap ifrs operating profit operating profit margin total assets ratio equity attributable owners company total assets profit attributable owners company profit attributable ratio profit annual dividend per share attributable owners company owners annual dividend per share b illion company e n dividend payout ratio billion otsuka group views distribution profits shareholders key management policy continue execute balanced return prof line profit growth jgaap ifrs jgaap ifrs profit attributable owners company ratio profit attributable owners company annual dividend per share dividend payout ratio due change consolidated fiscal year fiscal ended december transitional period covering nine months april december otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report nonfinancial highlights environmental data limited past three years due change collation criteria number employees number employees ghg emissions throughout ghg emissions ratio employees outside japan number value chain fiscal thousand tonsco emissions scope categories strive utilize diversified human resources order adapt acceleration global busi ness expansion varied social needs scope employee ratio outside japan increased approximately thousand tons co scope category category emissions use emissions sold products purchased goods services japan outside japan scope otsuka holdings subsidiaries female manager ratio number female managers female manager ratio water usage water usage female manager ratio number thousand thousand otsuka group believes active involve ment diverse human resources vital element growth company including strength ening systems invoke creativity respond demands society accordingly make efforts promote active participation female employees otsuka pharmaceutical otsuka pharmaceutical factory taiho pharmaceutical otsuka chemical otsuka warehouse japan outside japan otsuka foods scope companies nonconsolidated otsuka pharmaceutical otsuka pharmaceutical factory taiho pharmaceutical otsuka chemical otsuka warehouse otsuka foods total co emissions total co emissions resource recycling rate final disposal amount resource recycling rate thousand tonsco ton million tons thousand tonsco otsuka group working reduce total co japan emissions using renewable energy bio indonesia mass fuel making use energy efficient india fiscal total co emissions increased north america previous year mainly due acceleration south korea global expansion resulting expansion business activities overseas china europe total co emissions co emissions per sales final disposal amount resource recycling rate scope calculated consolidated subsidiaries otsuka group companies constitute top co emissions originating energy otsuka holdings co ltd integrated report number employees number employees ghg emissions throughout ghg emissions ratio employees outside japan number value chain fiscal thousand tonsco emissions scope categories otsuka group assesses environmental impacts throughout value chain five major compa scope nies japan large environmental impacts addition emissions corporate activities scope calculate emissions stemming thousand tons activities suppliers customers parties co scope continue efforts calculate scope emissions aim reducing scope co emissions throughout value chain category category emissions use emissions sold products purchased goods services japan outside japan scope companies nonconsolidated otsuka pharmaceutical otsuka pharmaceutical factory taiho pharmaceutical otsuka chemical otsuka foods female manager ratio number female managers female manager ratio water usage water usage female manager ratio number thousand thousand assess state water risk amount water used main manufacturing sites around world work achieve communitybased management effective use water resources achieve sustainable society japan outside japan scope calculated consolidated subsidiaries otsuka group companies constitute top co emissions originating energy total co emissions total co emissions resource recycling rate final disposal amount resource recycling rate thousand tonsco ton million tons thousand tonsco otsuka group companies japan japan promoting recycling reuse resources indonesia achieved recycling rate zero emissions india based internal standard higher north america recycling rate fiscal south korea continue striving zero emissions undertaking rs reduce reuse recycle china europe total co emissions co emissions per sales final disposal amount resource recycling rate scope major consolidated subsidiaries japan otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report message president delivering nextgeneration total healthcare world enduring corporate philosophy value creation leaps forward business contributing peoples health worldwide environment healthcare field changes occurring constantly due fac goal tors ageing populations changing patterns disease prevalence earlier diagnoses accompanying increase demand medicines global pharmaceutical market con tinued grow valued one trillion us dol lars competition scale growth also intensifying reflected frequency mergers acquisitions oftenrelated industry restructurings also escalating research development costs necessitate huge investment encouraging risksharing alliances simultaneously measures control optimize medical costs expanding us many countries aim curb ing increasing drug costs big wave technological innovation extended health care sector companies utilizing latest technologies including big data analysis artificial intelligence drug discovery devel opment led rising expectations medical breakthroughs development new drugs previously untreatable condi tions result seeing improving healthcare outcomes otsuka holdings co ltd integrated report tatsuo higuchi president representative director ceo different diseases geographies around world health care sector approaches major inflection points constantly ask need contribute thrive envi ronment answer simpleunwavering goals continued innovations since foundation group maintained unwavering com mitment corporate philosophyotsukapeople creating new products better health worldwide guided philosophy constantly pursued achieve ideally preanticipat ing changes business environment possi ble responding flexibly swiftly changes seeking meet universal aspiration people around world healthy regard healthcare wholebody domain activities based two pillars pharmaceutical business extends diagnosis diseases treatment nutraceutical business helps people maintain improve day today health walking alongside customers identify meet healthcare needs introduced innovative products services created markets previously exist otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report message president otsukas business contributing peoples health model pharmaceuticals nutraceuticals recent years many pharmaceutical companies based business review concentration strategy increasingly focused areas require deep specific expertise example emphasize new drug development areas oncology others ded icated generic drugs emerging economies amid trends otsuka group boldly choose business portfolio encompassing pharmaceuticals nutraceuticals two areas health unrelated fact closely related two sides coin two businesses contribute health peo ple compelling reason built port folio covering second apply exacting scientific standards apply prescription drug business development new nutraceutical products evaluation health benefits assures customers standards underpinning prod ucts highly credible creation products treatment prevention dis eases well maintenance improvement health precisely role otsuka group companies ful filled far advanced toward ultimate goal become indispensable contributor peoples health worldwide furthermore positive momentum spur strategy healthcare increasingly curing diseases also maintaining improving everyday health trend anticipated eventually improve quality life extend healthy life expectancy accordingly products services themes maintaining improving health showing excellent growth developing pharmaceutical nutraceutical businesses build resilient portfolio business structure conducive sustainable growth pharmaceuticals higherrisk higherreturn business rd succeeds look forward commensurate returns products launched hand multiple factors adversely affect earnings include expiration drug pat ents government measures reduce optimize medical costs exemplified lowering drug prices japan contrast nutraceuticals mediumrisk mediumreturn busi ness although expect profits margins akin pharma ceutical business build stable longterm earnings foundation able provide added value innovative products continuing invest solid brand image order achieve sustain able growth company must lay foundation believe diversified business portfolio gives us strength otsuka holdings co ltd integrated report otsuka group long proud history soon celebrate th anniversary founding point time pharma ceutical business main growth driver however nutraceutical business larger scale without nutraceutical business rd efforts resulting multiple drugs current growth drivers would succeeded dna core beliefs inherited since foundation competency foundation present based enduring prin ciples otsuka always committed manufacturing innova tive creative products contribute health people around world quest create deliver new value ask key questions things achieve pursuing innovative approach without captive existing concepts notions products appeal consum ers patients healthcare providers around world con tributing improvement peoples health whenever encounter difficulties return enduring prin ryukan godo calligraphic work otsuka founder ciples implicit corporate philosophy pursue business busaburo otsuka wavering goals succeeded take pocari sweat example consistently conveyed concept rehydration drink enables people easily replenish fluids electrolytes lost perspiration period time led creation new market ion drinks establishment brand growth pocari sweat result shortterm factors trends proof correctness decisions actions based corporate philosophy inherited three elements otsukas dna passed three past generations otsuka family leadersryukan godo pocari sweat created market sweat recognize way jissho actualization sozosei cre ion drinks ativity ryukan godo means core substance something discovered hard work practice jissho selfactu alization achievement completion discovery truth sozosei creativity epitomizes otsukas corporate culture today corporate group consolidated net sales nearly usd billion aforementioned three terms passed otsukas family leaders together venture spirit implicit corporate philosophy shared every employee deeply penetrate organization systems unchanging val ues govern daily business activities otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report message president becoming diversified human resources drive indispensable company business growth else required osaka group become indispensable contributor peoples health worldwide answers lie human resources innovation using two elements driving force applying knowledge technologies accumulated date fosters harmonious environment product creation hap pens innovative products bornproducts help us address health issues achieve sustainability otsuka group comprises employees diverse backgrounds encourage learn corporate culture share otsuka val ues emphasize creativity foster promote appropriate present otsuka group around employees across countries regions employees outside japan represent ing approximately workforce accepting sharing different languages cultures backgrounds experiences perspec tives create flexible openminded corporate culture respond appropriately diversification social needs glo balization business among various initiatives end otsuka became signa tory womens empowerment principles weps set action principles guide companies seeking foster advancement women continue strengthening organization promoting advancement women developing human resources nextgeneration leaders import ant management priority sustaining groups growth increas ing value innovative organization otsuka group undertakes wide range human resource development programs include opportunities employees learn corporate culture share values emphasize creativity together management study abroad mental physical health employee also essential achieve sustainable growth providing healthy support ive work environment key endeavor april issued otsuka group declaration health line strive create work environment employees exercise full abilities display originality promote health employees enhance organizational strength womens empowerment principles weps set action principles pre pared jointly united nations global compact united nations entity gender equality empowerment women human resource development corporate signatories april institute supports deployment diverse human resources otsuka holdings co ltd integrated report pursuing value customers timely innovations group creating new markets creating pharmaceuti cals address unmet medical needs well nutraceuticals address yettobe imagined needs consumers pharmaceutical business developed drug tablet embedded microchipthe worlds first digital medicine integrates pharmaceutical medical device recording ingestion medication aim advance care offered patients schizophrenia also developed one two new therapeutic agents past years treatment multidrug resistant tuberculosis mdrtb become serious health problem countries nutraceutical business meanwhile utilize new inline assets cultivated experience achievements date create various new innovations include food product contain ing soybeanderived equol resulting rd womens health giant tomato tree symbolizes nutritious foods aim help extend healthy life expectancy importance paradigm shifts necessitat ing abandonment preconceptions diversified workforce valuable perspectives contribute company create sustainable value together local communities accumulate assets repeat cycle virtuous innovation also returns portion profits society consideration csr business activities also important part becoming indispensable contributor peoples health worldwide progress extending fiscal results mediumterm plans final year management plan otsuka group forging ahead second mediumterm management plan covering fiveyear period fiscal feature second mediumterm plans emphasis investment sustainable growth management planp structural reforms aimed revenue diversification reinforcement core therapeutic franchises pharmaceutical business pursuit transformation structural reform nutraceutical business fiscal fourth year plan according schedule posted healthy increases sales new pharmaceutical products invested aggressively rd view next mediumterm management plan also entered numerous transactions including business acquisitions alliances licensing agreements set current plan achieved yearonyear increases revenue profit continued solid growth path pharmaceutical business posted steady increases sales three products marketed many countries abilify otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report message president maintena longacting injectable antipsychotic abilify new antipsychotic agent rexulti samscajinarc aquaretic agent several indications cardiac edema also treatment autosomal dominant polycystic kidney disease adpkd sales anticancer agent lonsurf europe greatly exceeded initial targets thanks growth new products solidified business foundation reinforced groups business foundation regula tory approvals us two products abilify mycite firstever digital medicine jynarque treatment inherited kid ney disease adpkd respect product development obtained rights centanafadine treatment attentiondeficit hyper activity disorder adhd acquisition neurovance also formed agreement covering japan teva pharmaceutical industries fremanezumab prevention migraine addi tion expanded geographic coverage collaboration akebia therapeutics joint development marketing vada dustat treatment renal anemia ways laid many cor nerstones next stage growth nutraceutical business reported solid performance post ing steady growth existing products expanding portfolio boost synergies specifically us posted healthy growth nutritional supplements businesses pharmavite foodstate europe nutrition sant performed steadily difficult eco nomic conditions expedite global expansion acquired daiya foods develops manufactures markets plantbased foods north america launched equelle us sup port womens health japan fostered new products par allel global expansion efforts highlights included launch bodymaint new brand conditioning food support athletic performance result nutraceuticals business achieved oper ating margin maintaining higher numerical target mediumterm management plan fiscal final year second mediumterm management plan year continuing diversification revenue struc ture plan launched antipsychotic agent abilify accounted around total net sales challenge secure sources revenue since however steadily implemented priority measures plan thanks growth core field achieving revenue diversification however initiatives insufficient targets remain unat tained address issues formulate execute strategies according corporate philosophy quest increase corporate value otsuka holdings co ltd integrated report governancerelated targeting sustained growth initiatives increased corporate value strengthening corporate governance priority quest achieve sustainable growth improve corporate value medium long term otsuka group established corporate governance guidelines november february formed corporate governance committee serve advisory body board directors aims strengthening increasing transpar ency governance also set otsuka group global code business ethics guide employees around world observe established otsuka group global anticorruption policy lays firm stance corruption codes pol icies require employee works high standard ethics fulfills responsibilities society addition company appointed three outside directors extensive experience insights multiple fields capable promot ing diversification deepening discussions board meetings incorporating management oversight function based fairminded research institute tokushima independent perspectives reaffirm whether deci prefecture birthplace otsuka group serves center improving sions board directors conform management corpo corporate value addressing health rate philosophies challenges november also became signatory united nations global compact declaring key obligations responsible corporate citizen signatory express support global compacts ideals time helping achieve sustainable development goals sdgs adopted united nations summit going forward continue addressing health issues inno vative products solutions emphasizing sustainable growth improved corporate value target ultimate goal become indispensable contributor peoples health worldwide invite stakeholders count otsuka group deliver nextgeneration total healthcare world ask contin ued support otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report feature second mediumterm management plan establishing diversified revenue structure achieve sustainable growth become indispensable contributor peoples health worldwide second mediumterm management plan hereinafter plan fiscal final year set forth strategic frameworks strengthening core therapeutic areas pharmaceutical business pur suing transformation structural reform growth nutraceutical business working material ize corporate philosophy contributing health people worldwide growth two core businesses realization sustainable growth establishing diversified business portfolio diversification business portfolio consumer products abilify business psychiatry businesses neurology excluding abilify fy fy fy target oncology nutraceutical cardiovascular business renal pharmaceuticals reducing reliance revenue diversification business portfolio establishment business abilify accompanying growth business areas foundation sustainable growth pharmaceutical business strengthening core therapeutic areas pharmaceutical business strengthen franchises centered psychiatry neurology oncol ogy areas order address unmet medical needs achieve creation new values early maximization value new products plan actively investing manage ment resources apply approvals add new indications expand sales areas aim early maximization value new product lineup driver growth billion new products consist three global products ratio new new pipeline composed antipsychotic agent longact products sales ing injectable abilify maintena generic pharmaceutical new pipeline business name aripiprazole antipsychotic agent rexulti billion generic name brexpiprazole vreceptor new pipeline new drugs japan antagonist samscajinarcjynarque generic name tolvaptan nextgeneration nextgeneration products products composed anticancer agent sgi billion lonsurf generic names trifluridinetipiracil sgi generic name guadecitabine new drugs japan fiscal final year global products plan raise percentage fy new products sales ratio compared fy fiscal pharmaceutical busi fy target ness work achieve diversification business portfolio otsuka holdings co ltd integrated report acceleration rd investments core therapeutic areas otsuka group seeks contribute patients around world new value creation achieved continuing highlevel rd investments original innovative product lineup plan continue highlevel investments rd work billion strengthen drug discovery capabilities max nd mtm plan imize value new product lineup drives growth focus core therapeutic areas time investing external assets strengthen development pipeline promise synergies knowhow assets group conduct ing rd activities aimed achieving sustainable growth resolving health issues lie beyond fiscal year rd expenses pharmaceutical business rd expenses ratio pharmaceutical business due change consolidated fiscal year fiscal ended december transitional period covering nine months april december new products expansion aggressive growth investment beginning nd mtm plan present europe japan us europe japan us rexulti filed dec otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report feature second mediumterm management plan establishing diversified revenue structure achieve sustainable growth become indispensable contributor peoples health worldwide nutraceutical business pursuing transformation structural reform growth nutraceutical business executing two strategies accelerating global expansion fostering new products undertaking structural reform business review business assets working establish business structure maintain operating profit margin accelerate global establishment expansion review business structure business assets maintain operating support profit value chain foster margin new products accelerate global expansion plan position growth global brands total sales outside japan fiscal pocari sweat nature made prod grew fiscal contributing greatly ucts nutrition sant one import growth profitability nutraceutical business ant strategies nutraceutical business ratio based jgaap fiscal ifrs fiscal acquisition fastgrowing plantbased foods manufacturer daiya foods daiya foods inc vancouver canada develops cheese alternatives yogurt alternatives dressings desserts made plantde rived ingredients backdrop growing health consciousness plantbased foods com pany continuing grow rapidly primarily north america adding new product category plantbased foods otsuka enhances product portfolio nutraceutical business seeking expanding business north america creating synergies sharing rd manufacturing tech nologies expertise growth smrofer larutcurts ot tcennoc topics otsuka holdings co ltd integrated report foster new products accelerating global expansion status fostering new products japan responding yettobeimagined needs japan actively investing management resources devel new solutions yettobeimagined needs opment fostering new products create fostering products original marketing new value new products working strategies grow japan well expand businesses side japan improve brand value womens health lifestyle habits launch equelle us kenjano equelle product con equelle kaimin taining equol support health beauty women steadily built new market contin ues grow since launch japan lifelong sports new areas october began sales us aim contrib research expanding bodymaint ute broadly maintenance healthy life expectancy promotion health women world wide wish combat discomfort natural means improve profitability reviewing business assets support value chain plan working reform business structure improve profitability sweeping review business assets support value chain review business assets support toward highly profitable business structure value chain maintains operating profit margin product strategies acceleration rd healthy life billion nd mtm plan rd expectancy production increased production efficiency new facilities investments marketing reconstruction creative pull mar sales keting based total health care distribution deployment matched markets fiscal year operating profit nutraceutical business operating margin nutraceutical business unaudited due change consolidated fiscal year business performance jgaap fiscal tnemeganam ecruoser namuh topics consumers otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report feature foundation supports growth strengths diverse employees organizational strength human resources one important business assets order otsuka group become indispensable contributor society group working nurture human resources aiming sustainable growth improve employee health create better work environments employ diverse range people goal furthering organizational strength strengthening development executive human resources training development nextgeneration executive human resources key issue group work grow sustainably creative innovative company create social values otsuka global academy operated human resources planning department otsuka holdings con number participants ducts executive human resource development pro executive human resource gram persons participated far development program program seeks improve aptitudes nextgen eration leaders strengthen management capabilities providing opportunities future leaders current management share values corporate culture emphasizes creativity health management health promotion employees physical mental health every creation work environment employees employee driving force asset support fully demonstrate capabilities individuality growth otsuka group work promote enhance organizational strength improve employee health health management concept ment employees health efforts understand maintain promote health february otsuka pharmaceutical employees lead creation inno otsuka pharmaceutical factory taiho pharmaceuti vation contribution society enhancement cal recognized certified excellent health organizational strength april formulated productivity management enterprise otsuka group health declaration promote excellent health produc tivity management enterprise program organized jointly ministry economy trade industry japan nippon kenko kaigi japan health council identifies large corporations small mediumenterprises practicing high level minute workout pocari fresh exercise week offices factories health productivity manage ment five hundred companies expect certified otsuka holdings co ltd integrated report diversity human resources creates new value order create groundbreaking products bring inno accurately flexibly diversification social vation accepted worldwide otsuka group needs internationalization businesses nurtured corporate culture eliminates barriers regarding promotion active participation job opportunities based nationality gender age women hold diversity forums undertake num disabilities strengthened initiatives diver ber initiatives including projects active participa sity recognition importance employing tion women also demonstrated management diverse human resources active involvements commitment group overall toward support currently employees otsuka ing women workplace becoming signatory group stationed outside japan recognizing womens empowerment principles weps sharing mutual differences language cul december ture building corporate culture respond percentage ratio employees female managers outside japan set principles created jointly united nations global compact united nations entity gender equality empowerment women april signed companies around world average six companies nonconsolidated otsuka pharmaceutical otsuka pharmaceutical factory taiho pharmaceutical otsuka chemical otsuka warehouse otsuka foods otsuka holdings subsidiaries otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report feature foundation supports growth strengths otsukas original marketing brandbuilding creation customer values nutraceutical business go beyond existing values preference convenience cre ate new markets new values original products leverage knowledge drug research pharmaceutical business proposing original scientific evidencebased products creating customer values yettobe nutraceutical business discern yetto imagined needs beimagined needs pursue creativity product value chain development sales development inheriting continually communicating sci originality entific evidencebased product concepts scientific evidencebased products develop expertise business marketing knowhow pharmaceutical business growth provision create customer values new markets product values brandbuilding creation customer accumulation values new knowhow markets pocari sweat creator new market pocari sweat product developed thorough nearly years since launch still con going research quickly rehydrate replen tinue provide wideranging information com ish electrolytes ions lost body sweat municates product concept pocari sweat however product launched grown brand enjoyed countries importance rehydration well understood regions primarily asia become product markets reaction unprece supports foundation sustainable growth dented beverage harsh group circumstances prioritized con sumers better understand products value concept based resolute commitment always responding difficulties going back corporate philosophy conducting business without wavering goals created new market ion bever ages people experience product vari ety scenarios involving sweating continuing communicate importance rehydration elec trolyte replenishment otsuka holdings co ltd integrated report calorie mate product pursued importance nutrition created balanced nutritional foods market development calorie mate goes back set sights sports nutrition thoroughly otsuka pharmaceutical started develop appealed importance balanced nutrition intake ment concentrated liquid food nutritional food athletes focused performance widened replace intravenous nutrition company understanding product concept estab modified concentrated liquid food nutritional lished position calorie mate product widely product general use calorie mate supported among athletes released balanced nutritional food since nutritional balance containing five major nutrients convenience calorie mate time however displaying gone beyond sports scenarios become calorie counts foods com part peoples lives including nutri mon difficult general tional calorie control dieting consumers grasp concept breakfast nutrition replenishment balanced nutritional food calo work study emergency supplies ries nutritional components indi way calorie mate created cated overcome situation new market balanced nutrition foods toward creation next new markets product development marketing activities help pharmacists professionals understand look ahead toward yettobeimagined needs equelle product value concept part otsuka group creating new markets estab challenge create next new markets lishing numerous brands creating customer values recent years launched initiatives aimed maximizing product value equelle devel oped theme womens health equelle food product made equol derived soy beans fermented proprietary lactic acid bacte ria developed otsuka pharmaceutical many years research soy beans since supplemented product equelle gele contains collagen calcium nutrients women seek offer information con duct learning programs specializing womens health otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report research development unmet yettobe medical imagined needs needs rd activitiespharmaceutical business otsuka group companies takes global approach rd rd expenses making steady rd investments leveraging innovative cre ativity operating companies rd powers groups billion aspiration create new markets contribute unmet medical needs innovative products inhouse drug discovery evolution otsuka groups rd rd innovation leveraging strengths otsuka groups drug discovery research built solid foundation rd expenses ratio continues drive originality innovation around otsuka pharmaceutical rd strengths areas psychiatry neurology taiho pharmaceutical possesses drug discovery technology platform prioritized oncology otsuka pharmaceutical factory leading company latephase development projects clinical nutrition astex pharmaceuticals pioneer fragmentbased drug discovery avanir pharmaceuticals particularly skilled develop ment neurology also joined group mutually sharing fus ing research platforms ideas companies across group otsuka group continues evolve rd structure yields new ratio inhouse drug discovery projects late phase development projects strengths innovation rd expenses pharmaceutical business phase ii later stage development december otsuka pharmaceutical otsuka pharmaceutical aims innovative drug discovery highly prioritized areas psychia cardiovas try neurology oncology allergy renal urology cular focus areas cardiorenal nephrology infec immunology tious diseases ophthalmology dermatology taiho pharmaceutical progress taiho pharmaceutical specializes three areas oncology universities fusion avanir pharmaceuticals psychiatry allergyimmunology urology bioventures open avanir pharmaceuticals focuses rd unmet neurology oncology particularly area oncol research institutions innovation otsuka group needs area neurology company strives ogy company pursues global consortia platform create treatments change daily life development mainly japan patients caregivers us europe asia support astex pharmaceuticals astex pharmaceuticals uses proprietary otsuka pharmaceutical factory clinical fragmentbased drug discovery technol nutrition ogy carry rd moleculartargeted otsuka pharmaceutical factory conducts rd drugs aimed molecules cause dis pharmaceuticals intravenous solutions eases oncology psychiatry core products underpinning medical care neurology areas earned high rep medical foods addition develops products utation worldwide leading company create new value addressing unmet needs fragmentbased drug discovery technology areas surgical aid regenerative medicine otsuka holdings co ltd integrated report rd activitiespharmaceutical business rd bases europe asia japan americas europe asia japan us uk china tokushima shiga tsuka pharmaceutical astex pharmaceuticals drug otsuka shanghai research institute otsuka pharmaceutical otsuka pharmaceutical fujii memorial research institute development discovery preclinical otsuka beijing research institute tokushima research institute hyogo commercialization inc development taiho pharmaceutical beijing co department medical innovations otsuka pharmaceutical ako research institute astex pharmaceuticals otsuka europe development ltd medicinal chemistry research clinical development commercialization ltd laboratories ibaraki avanir pharmaceuticals inc taiho pharma europe ltd south korea department cns research taiho pharmaceutical iscovery preclinical research division taiho oncology inc korea otsuka pharmaceutical co ltd formulation research institute tsukuba area germany otsuka novel products gmbh sin tg aia hp phr ae rma singapore pte ltd de iap ga nr otm ste icn ivf id sir ou ng rd dco dve er py rtt mra et ne tgy oo tsk uky ao pharmaceutical diagnostic division rd department taiho pharmaceutical headquarters clinical development discovery preclinical research otsuka pharmaceutical factory research development center division tokushima area clinical development department taiho pharmaceutical clinical development division otsuka pharmaceutical factory naruto research institute research osaka development center otsuka pharmaceutical headquarters clinical development b asic research technical center c linical development open innovation otsuka group otsuka group engages open innovation fuses strengths inhouse drug discovery research technologies knowledge bioventures academia collaboration among companies industryacademia collaboration achieve highly innovative drug discovery working strengthen inhouse drug discovery capabilities including human resources development access innovative technologies ideas involving research support networkbuilding bioven tures research institutions universities hold leadingedge research technologies drug discovery seeds progress universities fusion open bioventures innovation otsuka group research institutions platform consortia support focus aiming discovery innovative drugs otsuka pharmaceutical concluded comprehensive partner ship agreement advanced research osaka university researchers mainly worldclass chief researchers immunology frontier research center ifrec fields immunology biological imaging bioinformatics con selected among worldtoplevel research center program ducting innovative immunology researches otsuka pharmaceutical ministry education culture sports science technology aims fuse original drug discovery research ifrecs ifrec offers outstanding research equipment international advanced research discover innovative drugs contribute environment researchers focus research health people worldwide otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report research development projects phase ii later stages march psychiatry neurology c feo ad tue sgeneric name brand name origin indication c ro eu gn iot nry phase ii phev ae sl eo p iim ient f ilt ea dtus approved major depressive disorder eu jp schizophrenia eu opc brexpiprazole rexulti otsuka dopamine partial agonist pharmaceutical agitation associated dementia us eu alzheimers type bipolar l us eu posttraumatic stress disorder us eu asc aripiprazole sertraline otsuka jp major depressive disorder dopamine partial agonistselective serotonin reuptake inhibitor pharmaceutical asia avp dextromethorphan quinidine dyskinesia associated parkinsons avanir us nmda receptor antagonistsigma receptor agonist disease agitation associated dementia us eu alzheimers type avp deuteriummodified dextromethorphan quinidine avanir residual schizophrenia symptoms us nmda receptor antagonistserotonin norepinephrine reuptake inhibitorsigma receptor agonist traumatic brain injury us intermittent explosive disorder us eb centanafadine neurovance attention deficit hyperactivity disorder us norepinephrine dopamine serotonin reuptake inhibitor tas taiho duchenne muscular dystrophy jp pgd synthase inhibitor pharmaceutical lu aa nalmefene lundbeck alcohol dependence jp opioid receptor antagonist opc otsuka attention deficit hyperactivity disorder us serotonin norepinephrine dopamine reuptake inhibitor pharmaceutical tev fremanezumab teva migraine jp anticgrp antibody phase iiiii oncology c feo ad tue sgeneric name brand name origin indication c ro eu gn iot nry phase ii phev ae sl eo p iim ient f ilt ea dtus approved tas trifluridine tipiracil lonsurf taiho colorectal cancer asia interference function dna pharmaceutical gastric cancer jp us eu tas tegafur gimeracil oteracil folinate taiho gastric cancer jp asia antimetabolite pharmaceutical pronetu fosnetupitant helsinn chemotherapyinduced nausea vomiting jp nk receptor antagonist healthcare ovarian cancer us eu sgi guadecitabine astex acute myeloid leukemia jp us eu asia dna methyltransferase inhibitor myelodysplastic syndrome jp us eu asia astx astex myelodysplastic syndrome us dna methyltransferase inhibitor astx astex solid tumors lymphomas us iap inhibitor tas taiho nonsmall cell lung cancer jp us eu dutpase inhibitor pharmaceutical tas taiho prostate cancer jp multikinase inhibitor pharmaceutical tas taiho gastrointestinal stromal tumor jp hsp inhibitor pharmaceutical ocv otsuka acute myeloid leukemia jp asia wt targeted cancer vaccine pharmaceutical hf takara bio melanoma jp oncolytic virus otsuka holdings co ltd integrated report projects phase ii later stages march cardiovascular renal c feo ad tue sgeneric name brand name origin indication c ro eu gn iot nry phase ii phev ae sl eo p iim ient f ilt ea dtus approved autosomal dominant polycystic kidney us disease asia opc tolvaptan samscajinarcjynarque otsuka pharmaceutical hepatic edema asia v receptor antagonist syndrome inappropriate antidiuretic hor jp mone secretion akb vadadustat anemia associated chronic kidney akebia us eu hifprolyl hydroxylase inhibitor disease opc otsuka cardiac edema jp v receptor antagonist pharmaceutical event april areas c feo ad tue sgeneric name brand name origin indication c ro eu gn iot nry phase ii phev ae sl eo p iim ient f ilt ea dtus approved tas taiho stress urinary incontinence jp selective norepinephrine reuptake inhibitors pharmaceutical tac meiji detrusor underactivity overactive bladder jp opc delamanid deltyba otsuka multidrugresistant tuberculosis us mycolic acid biosynthesis inhibitor pharmaceutical multidrugresistant tuberculosis pediatrics eu opce rebamipide mucosta ophthalmic suspension otsuka dry eyeseye drops md multi dose jp pharmaceutical mucin secretagogue otsuka opf pharmaceutical peripheral parenteral nutrition solution jp glucose electrolyte amino acid fat vitamin factory opa otsuka atopic dermatitis jp pde inhibitor pharmaceutical ops otsuka clostridium difficile infection enteric infection jp asia new quinolone based antibacterial agent pharmaceutical diagnostics c feo ad tue sgeneric name brand name origin indication c ro eu gn iot nry phase ii phev ae sl eo p iim ient f ilt ea dtus approved ccac otsuka measurement gastric acidity jp ccalcium carbonate breath test pharmaceutical odkodkcn otsuka diagnosis myelodysplastic syndrome asia wt mrna rtpcr assay kit pharmaceutical odk otsuka graves disease jp thyroidstimulating autoantibody kit pharmaceutical otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report fiscal business results unmet yettobe medical imagined needs needs pharmaceutical business addressing unmet medical needs total healthcare solutions strategy diagnosis treatment disease nd mediumterm management plan business overview fiscal initiatives fiscal strengthen core therapeutic areas pharmaceutical business established business foundation future growth steadily increased sales new product lineup able make maximize product value active investment rd including strengthening development pipeline focus core therapeutic areas aimed accelerated growth made prepara aggressive rd investments core tions growth next mediumterm management plan beyond therapeutic areas fiscal marks final year second mediumterm management plan year completing establishment diversified revenue structure year maximize value new product lineup take strengthening business foundation active investment aimed sales ratio next stage growth sales external customers steady growth new product lineup net sales billion change fy fy antipsychotic abilify maintena antipsychotic rexulti aquareticadpkd treatment samscajinarc anticancer agent lonsurf new drugs japan products launched japan since except japan four products listed north america adpkd autosomal dominant polycystic kidney disease others business performance key topics h fiscal n segment sales attentiondeficit hyperactivity licensing agreement mylan disorder adhd drug candidate commercialize mdrtb therapeutic mar aug billion centanafadine added pipeline drug deltyba highburden acquiring neurovance us countries n segment profit antipsychotic rexulti accepted billion review ema adult patients worlds first digital medicine system schizophrenia europe nov abilify mycite approved us licensing agreement teva may pharmaceutical prophylactic migraine drug candidate fremanezumab japan antipsychotic rexulti approved jan schizophrenia japan jul licensing agreement rpharm commercialize multidrugresistant tuberculosis mdrtb therapeutic jynarque approved autosomal drug deltyba russia cis apr dominant polycystic kidney disease countries adpkd us antipsychotic longacting injectable abilify maintena approved bipolar disorder us brand name europe rxulti otsuka holdings co ltd integrated report pharmaceutical business social challenges unmet medical needs line evolution life sciences number new drugs discovered every year however still many diseases treatment satisfaction incomplete currently available therapeutic options effective treatment exists meeting peoples wish healthy universal pressing challenge see pages information unmet medical needs core therapeutic area otsukas strengths otsuka group companies resolutely commits total unmet medical needs based corporate corporate healthcare philosophy otsukapeople creating new products culture solutions better health worldwide areas psychia generates diagnosis try neurology oncology position innovation treatment core therapeutic areas leveraging longheld diseases knowledge assets global network address creation value health longheld knowledge global asset presence network core therapeutic areas unmet medical needs tuberculosis eradication unmet tuberculosis one mankinds released mdrtb treatment drug deltyba one medical oldest diseases resists eradica worlds first new treatments years needs tion although treatable dis deltyba placed model list ease every year million people essential medicines collaborated infected million die disease even global drug facility stop tb partnership today multidrugresistant tuberculosis mdrtb constructed framework supplying drug resists existing antituberculosis agents countries deltyba used become major health issue treatment cases mdrtb many years efforts aimed infectious countries continues contribute global pub diseases key theme since launch drug lic health discovery research otsuka pharmaceutical global tuberculosis report otsuka holdings otsukas goal business strategy business results csr governance finance general informationcontribution unmet medical needs optimization healthcare abilify advances solutions research agreement abilify acquisition agreement e keppra alliance agreement agreement psychiatry development launched exclusive rights development launched lundbeck development dig started commercialization us ucb devel commercialization japan cns area ital health products abilify oping market e keppra japan proteus digital bristolmyers squibb ing neupro patch ucb health company japan esihcnarf fo gninepeed otsuka holdings co ltd integrated report fy business results pharmaceutical business psychiatry neurology business foundation area psychiatry strength otsuka pharmaceutical adding assets neurology accelerate expansion strategy prioritized therapeutic area challenge addressing unmet medical needs otsuka group began research area psy area accelerating development avp chiatry continues efforts address address agitation alzheimerstype dementia unmet medical needs nextgeneration antipsy unmet medical needs contributing chotic agent rexulti successor antipsychotic patients nuedexta worlds treat abilify worlds first dopamine partial ago ment pseudobulbar affect pba addition nist contributing patients adjunctive therapy secured exclusive rights japan freman major depressive disorder schizophrenia ezumab prophylactic migraine drug candidate treatment expanding indications max teva pharmaceutical imize products value new treatment option innovation form longacting injectables attentiondeficit hyperactivity disorder adhd centana resolve medication adherence psychiatric disorders fadine drug candidate neurovance joined requiring longterm adherence worlds first digi otsuka group deepening franchise tal medicine abilify mycite digital health solu area together inhousedeveloped compound tions business seeks optimize medical treatment opc aim contribute comprehensively healthcare since avanir pharmaceuticals acquisition creation new value made fullscale entry area neurology neurology psychiatry digital health solutions fremanezumab centanafadine nuedexta opc avp rexulti digital medicine abilify mycite psychiatry longacting injectables solutions adherence abilify maintena rexulti abilify maintena month formulation otsukas business history psychiatry neurology otsuka holdings co ltd integrated report psychiatry neurology main products antipsychotic antipsychotic longacting injectable abilify abilify maintena generic name aripiprazole generic name aripiprazole primary sales region japan us europe asia primary sales region japan us europe asia features opamine partial agonist features dopamine partial agonist fy sales billion fy sales billion antipsychotic pseudobulbar affect pba agent rexulti nuedexta generic name brexpiprazole generic name dextromethorphan quinidine primary sales region japan us primary sales region us features nmda receptor antagonist features opamine partial agonist sigma receptor agonist fy sales billion fy sales billion antiepileptic dopaminergic antiparkinsonian agent restless e keppra legs syndrome agent neupro patch generic name levetiracetam generic name rotigotine primary sales region japan features djustment release neu primary sales region japan rotransmitter due binding synaptic vesicle glycoprotein features dopamin agonist fy sales billion fy sales billion copromoted ucb japan unmet medical needs area psychiatry neurology schizophrenia unmet medical schizophrenia psychiatric disor needs der thoughts emotions number patients schizophrenia continue disordered appearing adolescence age maturity presents symptoms hallucinations europe five countries delusions thought disorders emotional flattening thousand japan us lack motivation make employment living thousand thousand society difficult even today advance sci ence causes disease fully elu cidated need longterm therapy support aimed return society ameliorating symptoms another issue lack recognition schizophrenia epidemiology mature markets data disease reduced medication adherence due drdecision resources llc rights reserved reproduction distribution transmission publication prohibited reprinted side effects lead relapse patients permission abilify maintena neupro patch acquisition avanir rexulti launched onzetra xsail acquisition license agree launched us launched japan pharmaceuticals us launched us neurovance ment teva pharmaceutical fremanezumab japan otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report fy business results pharmaceutical business oncology cancer supportive care area oncology cancer supportive care aim total care standpoint patients expanding business cover fields solid tumors hematological cancer support ive care main products anticancer agent anticancer agent ts lonsurf generic name tegafur gimeracil oteracil generic name trifluridine tipiracil primary sales region japan europe asia primary sales region japan us europe features antimetabolic agent features dna dysfunction fy sales billion fy sales billion anticancer agent antiemetic drug abraxane aloxi generic name p aclitaxel proteinbound parti generic name palonosetron cles injectable suspension albuminbound primary sales region japan primary sales region japan features ht receptor antagonist features axane anticancer agent fy sales billion fy sales billion unmet medical needs oncology unmet reports million success rate existing treatments depending medical people worldwide one six peo type cancer age patient despite needs ple died cancer according astonishing advances drugs still many national cancer institute issues resolve oncology area fiveyear survival rate cancer patients us otsuka group continues take chal improved less lenge unmet medical needs aims make com data thanks advances diagnos prehensive contributions cancer treatment tic methods medical treatment however seer cancer stat facts cancer site still means approximately patients national cancer institute bethesda md survive five years diagnosis time httpseercancergovstatfactshtmlallhtml httpswwwcancergov significant disparities survival rate otsukas history oncology field license former futraful launched ts launched japan acquisition acquisition exclusive rights acquisition global busi soviet union introduce japan exclusive rights american biosciences ness rights busulfex anticancer agent futraful helsinn healthcare developing marketing pdl biopharma japan developing mar abraxane japan keting aloxi japan currently celgene corporation otsuka holdings co ltd integrated report cardiovascular renal system vreceptor antagonist samscajinarc aquareticadpkd treatment contributed healthcare worlds oral samscajinarc aquaretic agent facilitates excretion free generic name tolvaptan water without electrolyte loss also grow primary sales region japan us europe asia ing steadily worlds first treatment features vreceptor antagonist rare kidney condition autosomal dominant poly cystic kidney disease adpkd fy sales billion unmet medical needs renal systemthe incurable disease adpkd unmet adpkd genetic disorder prevalance rate among genetic kidney disorders medical large numbers cysts sacs contain said patients japan needs ing fluid form kidneys result europe us ing gradual weakening kidney currently cure adpkd samsca function half patients reach jinarcjynarque treatment world end stage renal disease requiring dialy controls progress adpkd sis kidney transplant disease high areas clinical nutrition intravenous solutions market share fy sales billion intravenous solutions otsuka group working clinical nutrition business years otsuka group japan otsuka pharmaceutical factory continues contribute large number patients leading company area intravenous solutions japan since expanded overseas well operating clinical nutrition business business companies overseas growing particularly fast indonesia egypt going ward group continue develop highvalueadded products meet market copyright iqvia calculated based jpm dec needs around world contribute global healthcare mat reprinted permission diagnostics agents fy sales billion companion diagnostics extremely important identifying individual differences effect drugs side effects providing right healthcare group provides diagnostics agents meet international stan dards including products support companion diagnostics wide range fields digestive respiratory infectious diseases cancer cardiovascular system companion diagnostics diagnostic testing used identify patients likely benefit particular therapeutic agent provide health care using optimal dosages agreement global col acquisition astex lonsurf launched agreement devel agreement develop agreement copromotion laboration oncology pharmaceuticals japan opment commer ment commercial keytruda msd bristolmyers squibb cialization iclusig ization lonsurf japan company japan asian europe coun countries ariad tries servier pharmaceuticals otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report fy business results nutraceutical business unmet yettobe medical imagined needs needs nutraceutical business nutraceutical business supports maintenance promo strategy tion everyday health original scientific evidencebased nd mediumterm management plan products fulfill yettobeimagined needs consumers structural reform evolution achieve growth business overview fiscal initiatives fiscal review business nutraceutical business advancing reforms create stable revenue assets support diversification sales structure toward priority measure accel value chain erating global expansion achieving steady growth health food brands acceleration global nature made united states well gerbl nutrition sant expansion rolling primarily europe asia pocari sweat global brands improve profitability japan expanding countries sales outside japan therefore lead ing growth nutraceutical business sales ratio fiscal maintain stable revenue structure product devel sales external customers opment value proposition leverages strengths otsuka group com panies work grow business scale accelerating global expansion key topics launched soyjoy crispy white acquired north american plant macadamia based foods manufacturer daiya feb jul foods inc japan north america launched antiseptic others mar oronine h ointment established new functional food treatment jul beverage affiliate otsuka minor skin conditions nutraceutical thailand ltd business performance injuries g lami fiscal nated tube size n segment sales billion launched equelle n segment profit launched bodymaint oct us apr conditioning food billion acquired french organic food prod dec uct manufacturer bc bio sas started test market ing kenjanokaimin may sleep rhythm support otsuka holdings co ltd integrated report nutraceutical business social challenges gap average life expectancy extension healthy life expectancy healthy life expectancy japan increase medical expenses years old years old average life expectancy japan among worlds highest men women large average life expectancy gap years men years women men life expectancy healthy life expectancy period healthy life years expectancy lifestyles hindered health prob lems moreover increasing medical expenses becom ing serious issue worldwide initiatives maintain average life expectancy promote health prevent disease expected women become increasingly important healthy life years expectancy source statistics health labour sciences research group otsukas strengths leveraging knowhow gained pharmaceutical business otsuka groups nutra original synergies ceutical business theme extending healthy product lines based pharmaceutical life expectancy provides world original prod scientific business ucts based scientific evidence support mainte evidence nance promotion everyday health following launch products partner inhouse laboratories research institutions gen erate research results results include bene fits water electrolyte replenishment long marketing flights activation brain intake balanced global based nutrition correlation equol production network product value capability premenstrual syndrome pms working improve brand value create customer value products fulfill yettobeimagined needs consumers research digestive tract nutrition research exercise nutrition otsu nutraceuticals research institute saga nutraceuticals research institute otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report fy business results nutraceutical business functional beverages sales ratio within segment pocari sweat oronamin c year launched year launched functional drink created new market carbonated nutritional drink containing vita ion drinks replenish water mins including vitamin c ions lost due perspiration globally expand ing mainly asia particularly sales ratio market share indonesia within segment tiovita drink solmack plus year launched year launched longselling product originally launched gastrointestinal remedy symptoms nau half century ago nutrient drink con sea due overeating overdrinking tains taurine vitamins carnitine chloride secondclass otc drugs designated quasidrug sales ratio within segment aminovalue os year launched year launched drink developed based knowledge acquired oral rehydration drink balance elec research branchedchain amino trolytes glucose based oral rehy acids bcaa clinical nutrition sports dration therapy advocated world health nutrition fields japans first foods function organization claim alleviation fatigue caused phys ical activity attributed functional component bcaa foods function claim fibemini bodymaint year launched year renewed year launched beverage g dietary fiber approved conditioning food containing otsuka food specified health uses regulate gas pharmaceuticals proprietary lactic bacteria trointestinal condition renewed b launched contribute mark th anniversary maintenance improvement health food specified health uses people concerned bodily condition euromonitor international sports beverage market aminovalue aminovalue powder strain isolated tokyo university agriculture otsuka pharmaceutical confirmed efficacy enhancing biological defense mechanismssales ratio within segment otsuka holdings co ltd integrated report functional foods nutritional nutritional supplements supplements sales ratio within segment functional foods sales ratio within calorie mate soyjoy segment year launched year launched product created new market bal soy bar baked fruit nuts soybean anced nutritional foods containing five major dough without using wheat flour nutrients three types jellies soyjoy crispy launched light launched tailored preferences settings crunchy bar sales ratio within segment gerbl nature made sales ratio year launched japan year launched japan within health food south france intro lineup nutritional supplements free segment duced providing nutrients tend fragrances food colorings preserva lacking modern diet natu tives first launched us nature ral ingredients like wheat germ fruits made established brand highquality sci brand growing market expansion entific evidencebased products glutenfree products europe foods function claim main products sales ratio within segment equelle oronaine h ointment year launched year launched product containing equol made lactic ointment treatment skin ailments acid fermented soy supporting womens health injuries tube packaging beauty also launched us changed aluminum laminate improving convenience secondclass otc drugs kenjanoshokutaku innersignal double support year launched year launched skincare brand women employs product uses dietary fiber digestionre active ingredient energy signal amp sistant dextrin slow bodys absorp obtained approval quasidrug new tion sugars lipids thereby reducing effects efficacy brighter complexion rise blood glucose levels triglycerides meal food specified health uses super fish oil lutein astaxanthin fish oil pearl gingko biloba launch year kenjanoshokutaku kenjanoshokutaku double support launched adenosine monophosphate ot otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report fy business results nutraceutical business global expansion nutraceutical business otsuka group companies carries business development addresses health issues needs every area based corporate philosophy contributing health people worldwide europe health issues growing awareness nutrition organic freefrom asia average annual growth rate health issues glutenfree market five major european countries importance water replenishment growing awareness health tropical diseases infectious diseases increase number people active sports average annual growth rate sports drink market asiapacific region otsukas challenge expansion organic foods glutenfree products nutrition health foods nutrition sant number countries otsukas challenge expansion pocari sweat countries regions including indonesia china uk germany spain france italy source euromonitor international retail value rsp share sales indonesia countries europe nutrition sant biocentury prod sports drinks ucts sold excluding japan source euromonitor international occ strategy consultants sarl global sales otsuka groups nutritional supplements business otsuka holdings co ltd integrated report global expansion nutraceutical business americas health issues spread growing awareness selfmedication nutrition primarily increase medical among millennial costs generation prevention allergenfree disease natural orientation average annual forecasted average growth rate us annual growth rate supplement market us cheese alternative market otsukas challenge nutritional supplements health foods business business expansion plant expansion pharmavites based foods business nature made entry daiya foods natural foods channels p fiscal sales growth compared daiya foods average annual previous year growth rate otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report fy business results consumer products businessother businesses consumer products business otsuka groups consumer products business delivers familiar sales ratio foods beverages delicious safe reassuring healthy sales external customers business overview fiscal initiatives fiscal consumer products business expanding focus retort pouch packed foods business represented bon curry size series beverages business represented match carbonated vitamin drink crystal geyser mineral water fiscal worked energize core brands expand base new customers though active marketing addition continued strengthening core brands fiscal work toward reforms enhance cost efficiency toward expansion business business performance new products offer added value size series fiscal n segment sales billion n segment profit main products billion bon curry match crystal geyser year launched year launched year launched japan worlds first commercially avail carbonated vitamin drink berry mineral water soft water bottled able food product retort pouch match flavor mixed directly spring water sourced bon curry released berries released mount shasta california featuring th anniversary first food function claims retort pouchpacked curry kcal size iine plus european style curry people concerned blood sugar level size series launched concept meals right size retort pouch lets customers easily visualize size meal micro waved packaging launched size iine plus added value plus aimed dispensing pharma cies product meets dietary habits contemporary society targeting people watching salt protein intake launched kcal size iine plus european style curry people concerned blood sugar level first food function claims retort pouchpacked curry size series contributes everyday health management superaged society otsuka holdings co ltd integrated report businesses expanding multiple directions encompassing chemical prod sales ratio ucts warehousing distribution businesses sales external customers business overview fiscal initiatives fiscal developing businesses segment multiple directions automotive electric electronic devices building materials medical fields including chem ical products business performs manufacturing sales various materials warehousing distribution business operates joint logistics business encom passing groups pharmaceuticals foods beverage logistics fiscal solidly expanded profits growth sales chemical products business steady trend volumes handled warehousing distribution business business performance fiscal continue accelerate new market development overseas fiscal domestically chemical products business logistics leveraging n segment sales based shared platform expand warehousing distribution business productivity improvements supply chain overall billion shared platform system enables efficient operation vehicles warehouses joint distri n segment profit bution products opposite natures summer winter products heavy light prod ucts system expected flatten fluctuations logistics achieve cost reductions efficient billion logistics greater quality main products services terracess poticon warehouse distribution friction material brake pads resin composite material used promotion joint logistics scalelike titanate potassium precision components sliding parts group products compa nies products commendation construction sustainable logistics system otsuka warehouse received meti ministers award excellent green logistics commendation program otsuka warehouse co ltd handles logistics pharmaceuticals products otsuka group companies received meti ministers award excellent green logistics commendation program december project reduction standby time productivity improvements carbon dioxide reduction establishment truckberth reservation system advance partnership seaos inc seino holdings co ltd award recognizes reduction standby times trucks fac tor long working hours drivers improvement productivity reduction co emissions made possi ble truckberth system developed seaos advance reservation truckberth times otsuka warehouse seino holdings otsuka warehouse continue partner manufacturers logistics make logistics efficient well create platform addresses contributes social issues ministers award recognizes businesses made remarkable contributions establishment sustainable logistics systems reductions environmental impacts logistics field productivity improvements logistics etc otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report csr business activities aiming become indispensable contributor peoples health worldwide otsuka group engages csr activities integrated businesses across entire value chain business activities strive compliance relevant laws assurance product quality safety reli ability appropriate provision information consideration environment cocreate sustainable value company communities otsuka engages csr five areas health environment quality culture employees detailed information csr activities please go otsuka group consolidated csr site httpswwwotsukacomencsrhdactivity rd themes ethical considerations concerning appropriate rd ethical considerations research using humanderived specimens considerations research using pathogenic microorganismsgenetically modified organisms ethics development nitiatives business partners suppliers csr procurement trengthening systems stable supply products establishment bcp bcm rd p procurement p production p quality safety control systems b information security p p strict quality control systems otsuka holdings co ltd integrated report otsuka pharmaceuticals tokushima itano factory built concept coexistence nature code practice information provision activities create customers value theme health basic policy measures counterfeit drugs r eflecting voices customers coexistence communities marketing information distribution p provision activities p patients consumers local communities p c environment compliance p p otsuka group global environmental council climate change response e stablishment global code business ethics initiatives protect water resources global anticorruption policy resource symbiosis initiatives enhancing internal whistleblowing system otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report csr business activities rd rd themes include outside members ensure appropriate otsuka group provides total support peoples ness credibility research committees health terms treatment diseases main examining research plans significance goals tenanceimprovement health order address research personal information management system unmet medical needs pharmaceutical business research progress status research outcomes engages rd theme tackling unmet standpoints ethical scientific validity areas treatment effective treatment options protection personal information available focus psychiatry neurol ogy oncology meet yettobeimagined needs nutraceutical business supports mainte considerations research using pathogenic nance improvement health conducts rd microorganismsgenetically modified original products grounded scientific evidence organisms theme expanding healthy life expectancy experiments using genetically modified organisms use pathogenic microorganisms research samples may contain otsuka group com ethical considerations concerning plies laws ordinances works toward appropriate rd prevention experimentrelated accidents toward use experimental animals verify efficacy consideration environment safety rd times necessary otsuka group setting internal rules examination complies related laws ordinances guide safety committees screening committees lines striving uphold scientifically valid method ologies ethical considerations viewpoints ethics development animal protection welfare including lives animals preservation environment development pharmaceuticals confirm safety experimenters safety effectiveness candidate compounds inhouse management system devel conducting clinical trials cooperation healthy oped implemented rules experiments individuals patients recognizing importance involve animals established animal experiment ethical considerations toward human rights per committee properly carry animal experiments sonal information otsuka group implements clinical breeding animal experiment committee eval trials compliance ethical principles stan uates whether proposed animal experiment plan dards including ichgcp international standard appropriate based rs principles implementation clinical trials pharmaceutical replacementavoidance replacement animal use products reductionminimization number animals used refinementminimization animal suffering based conduct researcher education inter nal inspections evaluations implementation experiments involving animals ethical considerations research using humanderived specimens conducting research using information spec imen collected human body tissues blood otsuka group complies laws guidelines conducts scientifically medi cally appropriate research consideration eth ics group company establishes committees otsuka holdings co ltd integrated report procurement initiatives business partners suppliers csr procurement order seek sustainable development building relationships trust formulating group group society believe collaboration wide procurement policies share policies business partners important conduct safe reliable business partners currently working formulate business activities consideration society com procurement guidelines pliance laws throughout value chain addition conduct evaluate questionnaires beginning dealings business partner concerning csr activities business partners perform investigations checks ensure quality work promote csr procurement going raw materials establish stable procurement beyond legal compliance assess business partners conclude basic trade agreements advance avoid status respect human rights labor environment risks also aim mutual sustainable development anticorruption measures fair equitable transparent procurement production strengthening systems stable supply products establishment bcp bcm otsuka group business continuity plans bcp place ensure group continues operate effectively possible able maintain sta ble supply products even largescale earth quakes disasters strike perspective business continuity management bcm incremen tally expanded scope since acquired iso certification august production stable supply medicinal products beverages foods acquired certification stable supply intrave nous solutions april followed stable supply anticancer drugs may continue work strengthen business continuity capabilities group overall furthermore conduct regular groupwide drills aimed verifying efficacy bcp confirming issues problems conducted joint drill major group companies based scenario earthquake directly tokyo worked strengthen response capabilities adaptability flexibility preparation unexpected bcp drill otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report csr business activities marketing information provision activities code practice rd awareness activities involving health otsuka group companies follow jpma promotion first oathas initiative conducting program code prescription drugs code behavior train supporters health women healthcare professionals formulated code practice otsuka group works forge boosting awareness rehydration electro relationships mutual trust stakeholders lyte replenishment including medical practitioners foster appropriate collab measure prevent heat disorder otsuka oration compliance issues social responsibility group delivering information impor clearly specify relationship pharmaceu tance rehydration electrolyte ion replenishment tical companies healthcarerelated organizations years expanding targets required striving ensure adherence standards information provision cover sports practitioners order fulfill responsibility pharmaceutical instructors people work construction sites company ensure practice proper medical care factories hot environments everyone based ethics patientoriented commitment children elderly hope support maintenance improvement health pro viding correct information raising awareness calling information provision activities create attention concerning heat disorder customers value theme health leveraging expertise knowhow gained years research development business activi ties involving health otsuka group works create customers value information provision activities aimed promoting awareness improving understanding health health promotion projects partnership prefectural metropolitan governments order make contributions social challenge expanding healthy life expectancy otsuka group working partnership local governments health awareness educational activities healthrelated themes include food education prevention life style diseases heat disorder countermeasures sports pro motion womens health disaster countermeasures communication health information otsuka group engages various forms infor otsuka advanced training healthy aging mation communication bring knowledge correct supporters oathas understanding health diseases people japan transitions superaged society variety systemic preparations made achieve com otsuka health comic library prehensive community care systems integrate hous launched otsuka health comic library ing medical care nursing care prevention lifestyle aim promotion childrens health deepening support time increasing attention placed role pharmacies centers communi tybased health information response voices pharmacies pharmacists medical professionals otsuka pharmaceutical launched pharmacy support pro gram oathas otsuka advanced training healthy aging supporters aim building framework providing education persons engaged health sup port oathas otsuka group offers proprietary pro grams leverage expertise gained otsuka holdings co ltd integrated report interest understanding concerning bodys cancer survivors families make improve mechanisms health one volume issued year ments lifestyles overcome challenges donate publications elementary schools life via survivorshipjp website based joint libraries throughout japan books used research shizuoka cancer center addition reading materials also educational materi otsuka pharmaceutical otsuka pharmaceutical als science health classes contributing factory provide easytounderstand information based promotion health studies knowledge knowhow gained though business activities via online pages health information communication websites illness iv solution nutrition respectively taiho pharmaceutical provides useful information distribution basic policy measures counterfeit drugs counterfeit pharmaceutical products products otsuka group launched global product secu contain indicated ingredients contain active rity gps team ensure pharmaceutical products ingredients indicated otherwise reach patients appropriate distribution channels present false labeling identity origin recent allow assurance quality monitoring years harm health due spread counterfeit markets working partnership industry pharmaceuticals become global issue government ensure safety patients patients consumers local communities reflecting voices customers specifications reduce cuts tiovita drink packag otsuka group prepared systems respond ing taiho pharmaceutical inquiries opinions requests concerning prod individual pack ucts reflects voices customers devel aging cases external opment improvement products cardboard boxes used tiovita drink series adoption universal design font taiho pharmaceutical otsuka pharmaceutical adopted specifications using ud font using universal drug name lessen sharpness cut surfaces reduce paper design font pack cuts opening product aging materials phar maceutical products toward packaging makes content clear make names drugs otsuka pharmaceutical easy patients read small packs pillow packaging used calorie mate understand printed flavor name make content font easily read clear even removed box basic con cept enabling many peo ple possible use modified otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report csr business activities coexistence communities good corporate citizen active local communities work invigorate communities interactions open factory otsuka pharmaceuticals tokushima itano factory holds yearly walk ing event together town itano theme importance health protection natu ral environment within grounds factory established natural forest allowing observation wild life biotope pond makes use cooling water factory makes open public otsuka pharmaceuticals tokushima wajiki factory also holds free illuminated cherry trees night outdoor concert open factory grounds door concerts together local viewing kitajima plant government works toward invigoration development community night viewing portion plant grounds also kitajima plant taiho pharmaceutical readied made available temporary refuge local citizens rows cherry trees walking paths grounds event disaster factory concluded holds seasonal events interaction com agreement local government allowing use munity include illumination cherry trees factory site restoration activities satu hati one heart indonesia indonesia pt amerta indah otsuka manufactures markets pocari sweat con ducts satu hati one heart social con tribution activities three themes education environment health activ ities aimed community development coexistence community edu cation area company constructs libraries donates books holds satu hati school teach science math children employees taking turns teacher library built satu hati school conducted way company active supporting edu kejayan factory cation children lead future free health clinic afghan refugees otsuka group established otsuka welfare clinic peshawar pakistan health clinic offered free medical treat ment afghan refugees requiring aid established operated cooperation among otsuka group companies companies involved healthcare business activities asia arab countries acted strong wish contrib ute directly health local people clinic contributed patients years activity shut fulfilling mission otsuka holdings co ltd integrated report inheritance traditional culture otsuka group origins tokushima works ren group awa odori dancers group otsuka phar pass regions traditional culture four ren maceutical otsuka pharmaceutical factory taiho pharmaceuti participating group awa odori dance fes cal puts forth company ren otsuka chemical otsuka foods otsuka warehouse take part jointly one ren tival tokushima boasts years history quality safety control systems duty healthcare company otsuka group therapeutic products act well japans food thinks first customers patients sanitation act group also promoting acquisi established rigorous quality control systems suited tion international certifications iso characteristics businesses includ quality iso medical devices iso ing pharmaceuticals cosmetics foods pursuit fssc food safety furthermore order product quality safety otsuka groups quality ensure thorough quality control adopted trace safety control systems comply legal require ability systems covering processes raw material ments governmental industry standards includ procurement production distribution sales ing japans pharmaceuticals medical devices b information security organized otsuka group information security social media addition group conducts regular committee share uptodate information informa emergency drills focusing core systems vital tion security review specific security measures database management otsuka group strives enhance level com otsuka group established privacy protection prehensive security throughout entire group management system protect customers valuable per continuously improve information security sonal information acquired personal information order counter risk cyberattack otsuka protection management system pms certification group enforces number measures arrang information security management system isms ing system security audits external expert body certification businesses appropriate diagnosing website vulnerabilities conducting drills related targeted email attacks monitoring posts otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report csr business activities please refer nonfinancial highlights pages data priority issues environment c environment otsuka group global environmental council group global companies contribute water resources resource management prior health people worldwide work sincerely reduce ity issues environmental initiatives begun impact global environment deliberations establishment longterm envi core businesses hope contribute cre ronmental vision consistent principles ation sustainable society protect nature united nations global compact information dis future earth closure global standards formulation established otsuka group global mediumterm environmental targets specific action environmental council composed group plans launch wide coordinator environmental managers looking ahead strengthen practice envi group company secretariat also formulated ronmental management meets social responsi otsuka group environmental policy guidelines bilities demands global society deepening advancing initiatives aimed environmental man understanding recognition environmental agement collaboration goes beyond problems environmental education employ boundaries otsuka group companies ees enhancing partnerships among otsuka group identified climate change group companies council organization otsuka group environmental policy global healthcare company responsi groupwide coordinator ble corporate citizen otsuka group always otsuka holdings co ltd take account global environment pur sues business activities group work environmental issues trademark qualities independence proactiveness creativity secretariat guidelines otsuka holdings co ltd provide products services otsuka pharmaceutical co ltd friendly environment contribute lowcarbon society contribute sound materialcycle society conserve biodiversity council members ensure compliance otsuka otsuka taiho otsuka otsuka actively engage social initiatives otsuka foods pharmaceutical pharmaceutical pharmaceutical chemical co warehouse co ltd enhance risk management co ltd factory inc co ltd ltd co ltd climate change response initiatives aimed efficient use energy acknowledge impacts climate change co reduction major risk facing group conducts businesses tokushima prefecture production sites global scale accordingly working group concentrated otsuka chemical tokushima mulate longterm reduction targets action plans city otsuka pharmaceutical factory itanogun sup achievement targets present group ply electric power steam neighboring group com working toward thorough energy conservation mea panies cogeneration systems adopted sures reduction co emissions striving promote efficient use energy use natural energy renewable energy sources reduce environmental impacts throughout group biomass fuels aimed achievement including effort otsuka pharmaceutical india society freed carbonbased fuels working reduce co emissions previous year making use biomass fuels otsuka holdings co ltd integrated report thirdparty verification greenhouse gas emissions resource symbiosis initiatives otsuka undergoes verification greenhouse gas emis aiming achieve recyclingoriented society sions scopes categories scope otsuka makes efforts improve resource usage thirdparty organizations improve transparency efficiency reduce generation wastes promote reliability environmental data also conduct ini initiatives toward rs reduce reuse recycle tiatives aimed understanding improving trends attain final waste disposal amount close zero emissions continue expand scope effort achieve zero emission internal verification enhance reliability data standard recycling rate least initiatives protect water resources initiatives aimed zero emissions group named water resources one prior group companies perform material recycling ity issues environmental initiatives assess water thermal recycling generated wastes resulted usage volume major production sites around recycling rate domestic group companies world along water risks issues also promote fiscal first achievement zero emissions regionally appropriate management effective usage group reduction final waste volume water seek preserve improve water resources achieved reduction tons previous year result companies working toward goals evaluation water risk manufacturing site otsuka chemical otsuka packaging industries watersheds en otsuka pharmaceutical making major contributions order engage appropriate water conservation reviewing disposal methods contractors activities taking regionspecific risks account processing reuse wastes raw materials undertook water risk assessment evaluation ingredients manufacturing site watersheds locations use heat energy generated incineration wastes countries using wri aqueduct tool provides water risk information free charge devel oped released world resources institute wri compliance establishment global code business enhancing internal whistleblowing system ethics global anticorruption policy japans corporate governance code calls estab order promote achieve groupwide compli lishment internal whistleblowing system indepen ance otsuka holdings established otsuka group dent management management oversight global code business ethics widely communi operational status system indepen cate stance initiatives code dence oversight function extremely important message president tatsuo higuchi whistleblowing system function quick president representative director ceo together detection illegal inappropriate conduct andor also formulated otsuka group information disclosure accordingly otsuka holdings global anticorruption policy expresses stance major group companies established whis prohibiting corruption sites worldwide tleblowing system independent management promote engagement business based high ensure whistleblowers use system sense ethics peace mind rules allow whistleblowing group company implement compliance fulltime employees also contract training covers standards rules least dispatched employees information whistleblow per year report status training reg ers reports strictly managed prevent ularly board directors meetings otsuka negative repercussions whistleblowers holdings operational status companies internal whis tleblowing systems reported regularly board directors meetings otsuka holdings otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report corporate governance basic approach otsuka holdings committed pursuing steady growth expectations stakeholders including customers corporate value medium longterm business partners employees local communities realizing corporate philosophy otsukapeople cre shareholders ongoing dialogue company ating new products better health worldwide articulates basic approach corporate governance meet commitment adheres basic policy corporate governance guidelines making transparent fair timely decisions fulfill ing corporate social responsibility living otsuka holdings corporate governance guidelines httpswwwotsukacomencompanygovernancepdfguidelinepdf governance system otsuka holdings board directors includes outside directors supervises execution quick reference march management plans ensure sustainable growth raise corporate value medium longterm form organization company audit fulfills roles responsibilities regarding improving supervisory board profitability capital efficiency otsuka holdings board directors eleven company audit supervisory board audit supervisory board members indepen outside directors three independent directors dent board directors take lead auditing term directors one year directors performance duties coordi nating accounting auditor internal audit audit supervisory board four members department ensures companys health maintains solid corporate governance system outside audit three independent directors deserve societys trust supervisory board members accounting auditor deloitte touche tohmatsu llc general meeting shareholders electsdismisses electsdismisses electsdismisses inquiry operational audits corporate board directors accounting audits audit supervisory governance response directors including outside directors board committee auditors including appointsdismisses outside members president representative cooperates director ceo cooperates accounting audits instructs reports accounting auditor internal audit department cooperates approval meetings material prior matters groups audit consultation management ex post facto guidance supervisory reports board subsidiaries shareholders meeting board directors audit supervisory board members etc otsuka holdings co ltd integrated report consists president director charge initiatives strengthen corporate governance administration outside directors president serves chair committee establishment otsuka holdings co ltd term directors set one year e audit supervisory board members audit decision adopt directors retirement benefits system corporate officer system adopted supervisory board two outside audit supervisory board members audit supervisory board members attend express three outside audit supervisory board members opinions meetings board directors monitor stock options performancelinked remuneration introduced legality soundness management shown stock publicly listed december directors performance duties audits audit first mediumterm management plan announced supervisory board core process striving two outside directors three outside audit supervisory board members improve audit effectiveness audit supervisory second mediumterm management plan announced board members also share information exchange opin three outside directors two outside audit supervisory board members ions appropriate relevant departments otsuka group global code business ethics established internal audit department internal control department corporate governance guidelines established administration department finance accounting internal whistleblowing system established externally otsuka holdings major group companies department well accounting auditor three outside directors three outside audit supervisory board members f evaluation effectiveness board directors effectiveness board directors evaluated stock options conditional progress mediumterm management january february every year otsuka holdings plan introduced conducts questionnaire survey directors audit corporate governance guidelines revised supervisory board members based outcomes corporate governance committee established survey company considers evaluates effec effectiveness board directors evaluated based questionnaire com tiveness entire board directors outcomes pleted directors audit supervisory board members reporting meetings held outside directors outside audit also reviewed company attorney evaluation supervisory board members improve understanding groups conducted previous fiscal year fiscal revealed management business issues regarding adequacy understanding knowl two female directors edge otsuka groups operations business among outside directors outside audit supervisory corporate organization board members address issues company company audit supervisory board otsuka strengthened support system ensure effective holdings board directors audit supervisory functioning board directors conducting regular board also engages independent accounting audi reporting meetings outside directors outside audit tor articles incorporation specify number supervisory board members directors shall exceed eighteen number evaluation effectiveness board audit supervisory board members shall exceed five directors conducted board directors held march effectiveness appropriateness b board directors board directors recognized eval accordance board regulations board directors uation items respect issues identified convenes month holds extraordinary meetings evaluationsuch ensuring diversity officers necessary make important business decisions super operations board directorsthe company vise execution operations work diligently enhance effectiveness board c director selection criteria directors entrench corporate governance otsuka holdings aims become indispensable con tributor peoples health worldwide targeting sus tainable growth improvements corporate value effectiveness evaluation questionnaire fiscal medium longterms help achieve goal appropriateness composition board directors also ensure diversity directors whole company adequacy understanding knowledge among individual appoints certain people directors people directors companys business fields specific corpo knowledge advanced expertise extensive experience rate strategies plans conducive realizing maintaining appropriate effec adequacy collaboration outside directors tive corporate governance internal directors particu adequacy collaboration audit supervisory board lar company comprehensively evaluates experience operation board directors expertise insights attributes candidates relationship governance ensure qualities required implement appropriateness functions board directors deter ing groups corporate philosophy otsuka group mining direction corporate strategies global code business ethics corporate strategies ii adequacy monitoring business respect implementing corporate strategies corporate governance committee iii adequacy embracing perspectives key investors seeking increase transparency objectivity stakeholders management otsuka holdings established corporate iv appropriateness risk management governance committee february advisory v adequacy collaboration informationsharing body board directors committee discusses group company deliberates nomination directors audit adequacy support system outside directors outside supervisory board members director remuneration struc audit supervisory board members ture levels corporate governance issues summary reports board directors committee otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report corporate governance g independent directorsaudit supervisory company past otsuka holdings established board members independence standards outside directors order selecting outside directors outside audit ensure independence standards set supervisory board members otsuka holdings looks companys corporate governance guidelines individuals great deal knowledge exten also apply outside audit supervisory board sive experience various fields company requires members candidates ability exercise adequate addition company registers outside direc management oversight function respect direc tors outside audit supervisory board members tors fair objective monitoring supervision independent directorsaudit supervisory board mem audit management neutral objective bers tokyo stock exchange since meet viewpoint addition requiring outside directors criteria independent directorsaudit supervisory involved business execution group board members established exchange rationale selection outside directors outside audit supervisory board members times attended fy name rationale selection board audit directors supervisory meeting board meeting mr kounose giving effective advice companys managers neutral expert perspective outside director abundant experience extensive knowledge cor tadaaki kounose porate manager well expertise food industry since risk conflict inter est visvis general shareholders moreover company believes mr kounose suitable independent director mr matsutani giving effective advice companys managers neutral expert perspective outside director abundant experience extensive knowledge med outside directors yukio matsutani ical welfare field well expertise healthcare industry since risk conflict interest visvis general shareholders moreover company believes mr matsutani suit able independent director company anticipates given abundant experience extensive knowledge corporate manager well expertise pharmaceutical industry mr sekiguchi able give ko sekiguchi effective advice companys managers neutral expert perspective outside direc tor since risk conflict interest visvis general shareholders moreover company believes mr sekiguchi suitable independent director mr sugawara specialized knowledge certified public accountant well abundant busi ness experience company determined able use experience hiroshi sugawara expertise audits company since risk conflict interest visvis general share holders moreover company designated mr sugawara independent audit supervi sory board member attorney ms wachi wellversed corporate legal affairs company determined outside audit able use experience expertise audits company since supervisory board yoko wachi risk conflict interest visvis general shareholders moreover company designated ms members wachi independent audit supervisory board member mr takahashi held major positions internal control departments many years abundant experience corporate management company determined kazuo takahashi able use experience expertise audits company since risk conflict interest visvis general shareholders moreover company designated mr takahashi independent audit supervisory board member note number board directors meetings audit supervisory board meetings attended outside director ko sekiguchi outside audit supervisory board member kazuo takahashi listed newly appointed th general meeting shareholders held march independence standards outside directors corporate governance guideline company determines outside director independent none following applies person relative within second degree kinship outside director currently past three fiscal years managing director executive officer executive operating officer important employee executive company one companys subsidiaries company outside director belongs executive one transactions otsuka group amount transactions fiscal year within past three fiscal years exceeds consolidated net sales either company outside director legal accounting tax expert consultant received remuneration exceeding million per fiscal year directly otsuka group excluding remuneration companys outside director fiscal year within past three years amount donation nonprofit organization outside director belongs executive otsuka group exceeded million total past three fiscal years amount exceeds income nonprofit organization otsuka holdings co ltd integrated report h internal audit department companys internal audit department reports remuneration directorsaudit directly president department regularly con supervisory board members ducts audits based internal audit rules ver remuneration system directorsaudit super ify operations executed appropriately visory board members designed ensure efficiently audits consider operations company attracts retains talented leaders moti regard assets overall affairs company vates deliver superior performance thereby affiliated companies department submits supporting steady growth groups earnings audit reports president directors audit corporate value supervisory board members need improve ment indicated department recommends actions amount director remuneration taken afterward confirms status company holding company implementation order optimize performance director remuneration consists fixed remuneration set companys duties department also shares infor depending position bonuses linked performance mation audit supervisory board members provide shortterm incentives stock options accounting auditor ways cooperates provide medium longterm incentives internal control department total remuneration officer category total companys internal control department handles remuneration type number applicable officers internal controls relating financial reporting company affiliated companies department total remuneration type million total number formulates rules manuals pertaining internal con officer remuneration amount officers category etc basic charged receive basic trols provides training ensures employees thor million remuneration cost bonus remuneration stock options oughly understand operational rules department works cooperation internal audit department directors excluding outside continuously monitor status operations thus directors establishing system ensuring executives reliably audit supervisory board assess internal controls members companys basic approach internal control excluding outside audit supervisory status establishment system described board members corporate governance report submitted outside directors tokyo stock exchange b amount director remuneration subsidiaries j corporate officer system operating companies otsuka holdings adopted corporate officer system remuneration directors subsidiaries clearly divides role corporate officer operating companies determined based execute business operations board duties responsibilities executing business directors make business decisions operating company based group strategies exercise supervisory function system ensures devised company well duties respon management transparency efficiency busi sibilities involving devising deciding strategy ness operations operating company strengthening corporate governance directors operating company k status accounting audit exceed cap director remuneration otsuka holdings signed auditing agreement resolved general meeting shareholders auditing firm deloitte touche tohmatsu llc audit companys accounts fair impar c amount remuneration companys audit tial stance certified public accountants audited supervisory board members companys accounts mitsuru hirano tsutomu audit supervisory board members essentially paid hirose koichi niki assisted ten basic remuneration variable compo certified public accountants four people nents based earnings certified public accountants audited companys accounts done continuously less seven years otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report directors audit supervisory board members march front row left masayuki kobayashi sadanobu tobe yoshiro matsuo ichiro otsuka tatsuo higuchi yuko makino atsumasa makise noriko tojo back row left ko sekiguchi yukio matsutani tadaaki konose yozo toba hiroshi sugawara yoko wachi kazuo takahashi directors chairman representative director president representative director senior managing director corporate executive director finance ichiro otsuka tatsuo higuchi administration yuko makino yoshiro matsuo apr joined otsuka pharmaceutical factory inc mar joined otsuka pharmaceutical co ltd apr joined otsuka pharmaceutical co ltd jun executive director director consumer jun senior managing director otsuka pharmaceutical apr joined otsuka pharmaceutical co ltd apr joined baxter limited products development division otsuka co ltd pharmavite jan operating officer associate general manager apr joined otsuka pharmaceutical co ltd pharmaceutical co ltd nov vice president executive director otsuka general affairs department otsuka mar director corporate finance accounting jun managing director responsible consumer pharmaceutical co ltd pharmaceutical co ltd department otsuka holdings co ltd products publicity promotion development jun executive director responsible us business jun operating officer general manager sep operating officer director corporate division otsuka pharmaceutical co ltd otsuka pharmaceutical co ltd general affairs department otsuka finance accounting department otsuka dec executive director research development jun president representative director otsuka pharmaceutical co ltd holdings co ltd otsuka pharmaceutical factory inc pharmaceutical co ltd nov senior operating officer general manager operating officer director accounting may representative director otsuka pharmaceutical jun executive director otsuka pharmaceutical co ltd general affairs department additional department otsuka pharmaceutical co ltd factory inc jul president representative director otsuka responsibility legal affairs external apr operating officer director tax department dec vice president representative director holdings co ltd current position relations otsuka pharmaceutical co ltd otsuka holdings co ltd otsuka pharmaceutical factory inc dec executive director otsuka chemical co ltd july managing director corporate administration operating officer director finance dec president representative director otsuka feb president representative director otsuka otsuka holdings co ltd accounting department otsuka pharmaceutical pharmaceutical factory inc pharmaceutical co ltd current position mar senior managing director corporate co ltd jul executive director otsuka holdings co ltd administration otsuka holdings co ltd mar executive director finance otsuka holdings co jun vice president executive director otsuka current position ltd current position holdings co ltd jan executive director otsuka medical devices co jun representative director otsuka pharmaceutical ltd current position factory inc vice chairman representative director otsuka holdings co ltd mar executive director otsuka pharmaceutical co ltd current position chairman otsuka pharmaceutical factory inc current position chairman representative director otsuka holdings co ltd current position executive director executive director executive director executive director sadanobu tobe atsumasa makise masayuki kobayashi noriko tojo apr senior managing director representative dec joined otsuka pharmaceutical co ltd oct joined taiho pharmaceutical co ltd apr joined goldman sachs japan corporation director shinko foods co ltd present day jun operating officer director odpi division aug president taiho pharma usa inc present day aug joined shearson lehman brothers holdings inc otsuka foods co ltd otsuka pharmaceutical co ltd taiho oncology inc jul engagement manager mckinsey company jul vice president representative director jun operating officer director finance department sep executive director taiho pharmaceutical co japan office otsuka foods co ltd oiaa division otsuka pharmaceutical co ltd jun director intel capital japan intel corporation nov vice president representative director ltd apr president ceo otsuka america inc aug managing director corporate development otsuka chemical holdings co ltd present day jun managing director finance accounting apr president representative director taiho otsuka holdings co ltd otsuka chemical co ltd otsuka pharmaceutical co ltd pharmaceutical co ltd current position feb executive director otsuka medical devices co may president representative director otsuka jul senior managing director corporate finance executive director taiho pharma usa inc ltd chemical holdings co ltd otsuka holdings co ltd apr chairman taiho oncology inc current apr president ceo otsuka america inc jul executive director otsuka holdings co ltd may chairman ceo otsuka america inc position aug executive director ceo pharmavite llc jun vice chairman representative director apr chairman otsuka america inc mar executive director otsuka holdings co ltd jan president representative director otsuka otsuka foods co ltd mar executive director otsuka foods co ltd current position medical devices co ltd current position jun chairman representative director otsuka current position may executive director otsuka america inc current chemical co ltd mar president representative director otsuka position jun vice chairman otsuka foods co ltd foods co ltd current position aug chairman pharmavite llc current position jun standing audit supervisory board member executive director otsuka holdings co ltd mar executive director otsuka holdings co ltd otsuka holdings co ltd current position current position nov president representative director otsuka foods co ltd jun executive director otsuka holdings co ltd current position mar chairman otsuka foods co ltd current position otsuka holdings co ltd integrated report directors outside director outside director outside director tadaaki konose yukio matsutani ko sekiguchi apr joined snow brand milk products co ltd apr intern pediatric department st lukes apr joined mitsubishi corporation present day megmilk snow brand co international hospital may joined boston consulting group ltd oct joined ministry health welfare jan general manager sterrad business division jun president representative director snow present day ministry health labour johnson johnson medical k k present day brand milk products co ltd welfare johnson johnson k k medical company oct president representative director aug directorgeneral health policy bureau nov president representative director megmilk snow brand co ltd ministry health labour welfare janssen kyowa co ltd present day janssen apr director advisor megmilk snow aug director national sanatorium tama zenshoen pharmaceutical k k brand co ltd april president national institute public health jul chairman director janssen kyowa co ltd jun special advisor megmilk snow brand dec vice president international university oct supreme advisor janssen kyowa co ltd co ltd health welfare current position jan representative director dia japan present day sep administrative council member university mar outside director otsuka holdings co ltd sh dia japan current position miyazaki national university corporation current position apr outside director nic corporation present day current position solasto corporation current position jun outside director otsuka holdings co ltd mar outside director kenedix inc current position current position mar outside director otsuka holdings co ltd current position audit supervisory board members standing audit supervisory board outside audit supervisory board outside audit supervisory board outside audit supervisory board member member member member yozo toba hiroshi sugawara yoko wachi kazuo takahashi apr joined otsuka chemical co ltd oct joined chuo audit corporation apr registered attorney law daiichi apr joined ebaraudylite co ltd present day jan director information center otsuka chemical oct joined deloitte touche tohmatsu present day tokyo bar association jcu corporation co ltd deloitte touche tohmatsu llc joined kajitani law offices current mar executive director strategic planning ra jan cfo trocellen gmbh feb vice president capital management co position institute co ltd may operating officer information system ltd current position jun corporate auditor nichias corporation nov executive director general manager department otsuka chemical holdings co jun outside audit supervisory board member current position system division sunkus associates inc ltd present day otsuka chemical co ltd otsuka holdings co ltd current position mar outside audit supervisory board member oct executive director head information jun corporate officer director corporate jun outside audit supervisory board member otsuka holdings co ltd current position system division circle k sunkus co ltd finance accounting department otsuka otsuka pharmaceutical co ltd may executive director chief management holdings co ltd oct outside director nippon parking strategy office customer franchisee dec executive director corporate administration development co ltd relations office internal control accounting otsuka chemical co ltd mar audit supervisory board member otsuka environmental management office circle k mar executive vice president corporate finance pharmaceutical co ltd current position sunkus co ltd accounting corporate service department may executive director head area franchise otsuka holdings co ltd circle k sunkus co ltd mar standing audit supervisory board member may executive director head information otsuka holdings co ltd current position systems division circle k sunkus co ltd mar outside audit supervisory board member otsuka holdings co ltd current position otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report main data effect fiscal ended december otsuka adopted international financial reporting standards ifrs information fiscal ended december also presented line ifrs millions us billions yen dollars jgaap jgaap ifrs ifrs item results net sales operations selling general administrative expenses research development expenses rd ratio operating profit operating profit margin profit attributable owners company financial total assets position total equity ratio equity attributable owners company total assets roe cash flows net cash flows operating activities net cash flows investing activities free cash flows dividends annual dividend per share yen dividend payout ratio common stock number shares outstanding h u n stock price yearend shares stock price yearend yen number total persons employees japan persons outside japan persons female manager number female managers persons ratio female manager ratio environmental total co emissions h n u ca data japan outside japan co emissions per sales n l li n thousand water usage resource recycling rate item names according ifrs names jgaap correspond names ifrs follows net incomeprofit attributable owners company net assetstotal equity sga expense jgaap presented total expense less rd expenses company believes useful investors comparing companys financial results jgaap ifrs due change consolidated fiscal year fiscal ended december transitional period covering nine months april december us dollar amounts report represent translations japanese yen solely readers convenience rate us approximate exchange rate december otsuka holdings co ltd integrated report millions us billions yen dollars jgaap jgaap ifrs ifrs item results net sales operations selling general administrative expenses research development expenses rd ratio operating profit operating profit margin profit attributable owners company financial total assets position total equity ratio equity attributable owners company total assets roe cash flows net cash flows operating activities net cash flows investing activities free cash flows dividends annual dividend per share yen dividend payout ratio common stock number shares outstanding stock price yearend stock price yearend yen number total persons employees japan persons outside japan persons female manager number female managers persons ratio female manager ratio environmental total co emissions data japan outside japan co emissions per sales thousand water usage resource recycling rate number employees otsuka holdings subsidiaries figures operating companies japan environmental data limited past three years due change collation criteria calculated consolidated subsidiaries otsuka group companies constitute top co emissions originating energy figures major consolidated subsidiaries japan otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report consolidated financial statements otsuka holdings subsidiaries year ended december consolidated statement financial position millions us billions yen dollars assets current assets cash cash equivalents trade receivables inventories income taxes receivable financial assets current assets subtotal assets held sale total current assets noncurrent assets property plant equipment goodwill intangible assets investments associates financial assets deferred tax assets noncurrent assets total noncurrent assets total assets us dollar amounts report represent translations japanese yen solely readers convenience rate us approximate exchange rate december consolidated financial statements notes consolidated financial statements refer consolidated financial statements httpswwwotsukacomenirlibraryreporthtml otsuka holdings co ltd integrated report millions us billions yen dollars liabilities equity liabilities current liabilities trade payables bonds borrowings financial liabilities income taxes payable provisions current liabilities subtotal liabilities directly associated assets held sale total current liabilities noncurrent liabilities bonds borrowings financial liabilities net defined benefit liabilities provisions deferred tax liabilities noncurrent liabilities total noncurrent liabilities total liabilities equity equity attributable owners company share capital capital surplus treasury shares retained earnings components equity total equity attributable owners company noncontrolling interests total equity total liabilities equity otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report consolidated financial statements otsuka holdings subsidiaries year ended december consolidated statement income millions us billions yen dollars net sales cost sales gross profit selling general administrative expenses research development expenses share profit associates income expenses operating profit finance income finance costs nonoperating income expenses profit taxes income tax expenses profit year attributable owners company noncontrolling interests earnings per share yen us dollars basic earnings per share diluted earnings per share consolidated statement comprehensive income millions us billions yen dollars profit year comprehensive income components reclassified profit loss remeasurements defined benefit plans financial assets measured fair value comprehensive income share comprehensive income associates subtotal components may reclassified profit loss foreign currency translation reserve cash flow hedges share comprehensive income associates subtotal total comprehensive income comprehensive income attributable owners company noncontrolling interests us dollar amounts report represent translations japanese yen solely readers convenience rate us approximate exchange rate december consolidated financial statements notes consolidated financial statements refer consolidated financial statements httpswwwotsukacomenirlibraryreporthtml otsuka holdings co ltd integrated report consolidated statement changes equity billions yen equity attributable owners company components equity financial noncon cs ah pa itr ae l sc ua rp pi lt ua sl sre ha reu sry r eae rta ni ne gd br ee ndm ee ee fin fia tt n ss pe u lo ar fe n va pous l rtus r ehee e hedt erts ha n cm rt soo vuaa eg ir h tf ino ocr ne rg ern sa enc rsu vlr ea c ha esh gfl eo sw total total intr el rl ein sg ts total equity income balance january profit year comprehensive income comprehensive income purchase treasury shares dividends sharebased payment transactions changes ownership interests subsidiaries result loss control transfer components equity retained earnings total transactions owners etc balance december balance january profit year comprehensive income comprehensive income purchase treasury shares dividends sharebased payment transactions changes ownership interests subsidiaries result loss control transfer components equity retained earnings total transactions owners etc balance december millions us dollars equity attributable owners company components equity financial noncon cs ah pa itr ae l sc ua rp pi lt ua sl sre ha reu sry r eae rta ni ne gd br ee ndm ee ee fin fia tt n ss pe u lo ar fe n va pous l rtus r ehee e hedt erts ha n cm rt soo vuaa eg ir h tf ino ocr ne rg ern sa enc rsu vlr ea c ha esh gfl eo sw total total intr el rl ein sg ts total equity income balance january profit year comprehensive income comprehensive income purchase treasury shares dividends sharebased payment transactions changes ownership interests subsidiaries result loss control transfer components equity retained earnings total transactions owners etc balance december us dollar amounts report represent translations japanese yen solely readers convenience rate us approximate exchange rate december consolidated financial statements notes consolidated financial statements refer consolidated financial statements httpswwwotsukacomenirlibraryreporthtml otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report consolidated financial statements otsuka holdings subsidiaries year ended december consolidated statement cash flows millions us billions yen dollars cash flows operating activities profit taxes depreciation amortization expenses impairment loss reversal impairment loss share loss profit associates finance income finance costs nonoperating income expenses decrease increase inventories decrease increase trade receivables increase decrease trade payables subtotal interest dividends received interest paid income taxes paid net cash flows used operating activities cash flows investing activities proceeds sales property plant equipment payments acquisition property plant equipment payments acquisition intangible assets proceeds sales redemption investments payments acquisition investments payments acquisition subsidiaries decrease increase time deposits net cash flows used investing activities cash flows financing activities purchase treasury shares increase decrease current borrowings proceeds noncurrent borrowings repayments noncurrent borrowings dividends paid net cash flows used financing activities increase decrease cash cash equivalents cash cash equivalents beginning period effect exchange rate changes cash cash equivalents cash cash equivalents end period us dollar amounts report represent translations japanese yen solely readers convenience rate us approximate exchange rate december consolidated financial statements notes consolidated financial statements refer consolidated financial statements httpswwwotsukacomenirlibraryreporthtml otsuka holdings co ltd integrated report group structure overview main operating companies otsuka pharmaceutical co ltd holistic healthcare company supporting wholebody health helping cure disease promotion everyday health keeping corporate philosophy company expanding businesses along two core businesses pharmaceutical business provides breakthrough treatments patients around world nutraceutical business helps healthy people get even healthier otsuka pharmaceutical factory inc original company otsuka group leader infusion developing intravenous solutions business years japan best partner clinical nutrition management vision company creates innovative products meet variety needs pharma ceuticals medical devices oral rehydration solutions medical foods otc drugs company expanding businesses glob ally mainly japan asia taiho pharmaceutical co ltd pioneer oral anticancer agents japan taiho pharmaceutical aspires agile specialty pharmaceutical company trusted world true corporate philosophy strive improve human health contribute society enriched smiles also taking challenge developing original pharmaceuticals contribute society consumer healthcare business taiho pharmaceutical also strives create develop unique brand consumers loyal years come otsuka warehouse co ltd contributing peoples health worldwide field logistics since founding otsuka warehouse consistently engaging logistics pharmaceuticals food products built common distri bution platform otsuka group three product areas pharmaceuticals food beverages daily necessities recent years com pany grown offer logistics services outside group otsuka chemical co ltd developing organic inorganic chemicals fine chemicals specialty chemicals new age otsuka chemical aims improve lives health people well environment business activities offers products mate rials meet wide range needs society manufacturer develops original technologies otsuka chemical supports customers aims continue grow trusted company provides value society otsuka foods co ltd creating high valueadded products offer new dietary lifestyles since founding taking company begins people food begins spirit motto otsuka foods conducts businesses areas foods bev erages deliciousness safety peace mind better health spirit foods among employees continue develop com pany delivers products allow customers live healthy lives create new dreams foods otsuka medical devices co ltd overseeing medical devices business otsuka group otsuka medical devices seeks grow medical devices business operates mainly asia including japan china one groups core businesses company striving spur growth group bringing together groups medical device experience expertise meet new healthcare needs otsuka holdings otsukas goal business strategy business results csr governance finance general information otsuka holdings co ltd integrated report global network otsuka group consists europe companies worldwide operating common theme health japan north otsuka operates america asia countries regions middle east south america oceania japan japan americas us canada brazil countries europe uk sweden germany switzerland belgium france italy spain czech republic portugal regions asia middle east china south korea taiwan philippines vietnam thailand indonesia india singapore turkey pakistan egypt oceania australia new zealand number operations employees companies employees japan japan approx approx outside japan outside japan approx treasury securities shares companies financial institutions factories research institutes corporations breakdown shareholders japan japan type outside japan outside japan individuals overseas others corporations history global business expansion north america us africa western europe south america eastern europe china india turkey australia asia thailand egypt spain brazil czech republic december otsuka holdings subsidiaries affiliates companies otsuka holdings co ltd integrated report corporate information shareholder information europe corporate profile december company organization april company name otsuka holdings co ltd shareholders meeting internal control department internal audit department established july nutraceutical business global strategy japan north capital billion planning headquarters america board directors corporate planning department head office kandatsukasamachi chiyodaku tokyo asia global business support department japan middle east finance accounting department tokyo headquarters shinagawa grand central tower konan chairman south minatoku tokyo japan project office america oceania president tax department telephone corporate service department number employees consolidated business development department business description control management related activities investor relations department respect companys subsidiaries affili administration department ates active pharmaceutical industry nutra president office ceutical industry consumer products public relations department areas human resources department url httpswwwotsukacomen human resources planning department planning department statutory auditors board statutory legal affairs department auditors statutory auditors office shares december number shares authorized shares number shares issued shares approx number shareholders principal shareholders top shareholders stock distribution number sharehold treasury securities name shareholder shares held ing ratio shares companies thousand nomura trust banking co ltd otsuka founders shareholding fund trust account financial master trust bank japan ltd trust account institutions japan trustee services bank ltd trust account corporations breakdown shareholders otsuka estate co ltd type otsuka group employee shareholding fund awa bank ltd state street bank west client treaty japan trustee services bank ltd trust account otsuka asset co ltd individuals overseas others corporations japan trustee services bank ltd trust account number shares held rounded nearest thousand although company holds shares treasury shares excluded list shareholding ratio calculated treasury shares deducted website information otsuka holdings website visit website httpswwwotsukacomen otsuka holdings otsuka 's goal business strategy business results csr governance finance general informationsignificance corporate symbol symbolic representation otsuka groups corporate philosophy corporate symbol adopts initial corporate name motif representing sky large rendered gradations otsuka blue small otsuka red represents focused energy otsuka wellspring tenets offsetting two forms poised balance otsuka name spelled open friendly typeface corporate symbol conveys otsuka groups energetic commitment human happiness good health